col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


653 Results       Page 1

 [1] 
Elsevier: The Lancet Infectious Diseases
  original article Date Title Authors   All Authors
1 [GO] 2024―Feb―22 Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies Eero Poukka, Kari Auranen, Ulrike Baum
2 [GO] 2024―Feb―22 Non-COVID-19 hospitalisation as a negative control outcome in COVID-19 vaccine effectiveness studies - Authors' reply Christian Holm Hansen, Ida Rask Moustsen-Helms, Morten Rasmussen, Bolette Søborg, Henrik Ullum, Palle Valentiner-Branth
3 [GO] 2024―Feb―15 Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices - Author's reply You Li
4 [GO] 2024―Feb―15 Evolution of respiratory syncytial virus burden in young children following the COVID-19 pandemic: influence of concomitant changes in testing practices Inès Fafi, Zein Assad, Léa Lenglart, Zaba Valtuille, Naïm Ouldali
5 [GO] 2024―Feb―07 Persistent SARS-CoV-2 infection: significance and implications Heather M Machkovech, Anne M Hahn, Jacqueline Garonzik Wang, Nathan D Grubaugh, Peter J Halfmann, Marc C Johnson, et al. (+5)
6 [GO] 2024―Feb―02 Persistence of immune responses of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, et al. (+5)
7 [GO] 2024―Jan―25 Power and the powerless: COVID-19 impact in southern Africa Phoebe Ashley-Norman
8 [GO] 2024―Jan―08 Antiviral humoral immunity against SARS-CoV-2 omicron subvariants induced by XBB.1.5 monovalent vaccine in infection-naive and XBB-infected individuals Yusuke Kosugi, Yu Kaku, Alfredo A Hinay, Ziyi Guo, Keiya Uriu, Minoru Kihara, et al. (+6)
9 [GO] 2024―Jan―05 Short-term effectiveness of the XBB.1.5 updated COVID-19 vaccine against hospitalisation in Denmark: a national cohort study Christian Holm Hansen, Ida Rask Moustsen-Helms, Morten Rasmussen, Bolette Søborg, Henrik Ullum, Palle Valentiner-Branth
10 [GO] 2024―Jan―03 Virological characteristics of the SARS-CoV-2 JN.1 variant Yu Kaku, Kaho Okumura, Miguel Padilla-Blanco, Yusuke Kosugi, Keiya Uriu, Alfredo A Hinay, et al. (+7)
11 [GO] 2023―Dec―20 Changes in the global hospitalisation burden of respiratory syncytial virus in young children during the COVID-19 pandemic: a systematic analysis Bingbing Cong, Uğurcan Koç, Teresa Bandeira, Quique Bassat, Louis Bont, Giorgi Chakhunashvili, et al. (+47)
12 [GO] 2023―Dec―20 Immunogenicity and safety of a booster dose of a self-amplifying RNA COVID-19 vaccine (ARCT-154) versus BNT162b2 mRNA COVID-19 vaccine: a double-blind, multicentre, randomised, controlled, phase 3, non-inferiority trial Yoshiaki Oda, Yuji Kumagai, Manabu Kanai, Yasuhiro Iwama, Iori Okura, Takeshi Minamida, et al. (+5)
13 [GO] 2023―Dec―20 Self-amplifying RNA vaccines against antigenically distinct SARS-CoV-2 variants Sander Herfst, Rory D de Vries
14 [GO] 2023―Dec―15 Post-viral sequelae of COVID-19 and influenza Monica Gandhi
15 [GO] 2023―Dec―15 Long-term outcomes following hospital admission for COVID-19 versus seasonal influenza: a cohort study Yan Xie, Taeyoung Choi, Ziyad Al-Aly
16 [GO] 2023―Dec―15 Fast evolution of SARS-CoV-2 BA.2·86 to JN.1 under heavy immune pressure Sijie Yang, Yuanling Yu, Yanli Xu, Fanchong Jian, Weiliang Song, Ayijiang Yisimayi, et al. (+10)
17 [GO] 2023―Dec―07 A synbiotic preparation (SIM01) for post-acute COVID-19 syndrome in Hong Kong (RECOVERY): a randomised, double-blind, placebo-controlled trial Raphaela I Lau, Qi Su, Ivan S F Lau, Jessica Y L Ching, Martin C S Wong, Louis H S Lau, et al. (+10)
18 [GO] 2023―Dec―07 Synbiotics in post-acute COVID-19 syndrome-a potential new treatment framework? Betty Raman, Maheshi N Ramasamy
19 [GO] 2023―Dec―06 SARS-CoV-2 mucosal neutralising immunity after vaccination Edward J Carr, Guilia Dowgier, David Greenwood, Lou S Herman, Agnieszka Hobbs, Martina Ragno, et al. (+32)
20 [GO] 2023―Nov―28 Lessons from the English primary care sentinel network's response to the COVID-19 pandemic Simon de Lusignan, FD Richard Hobbs, Aziz Sheikh
21 [GO] 2023―Nov―22 Oral and intravenous 1'-cyano-substituted adenosine-like antivirals for early COVID-19 Robert L Gottlieb, Roger Paredes
22 [GO] 2023―Nov―22 Oral VV116 versus placebo in patients with mild-to-moderate COVID-19 in China: a multicentre, double-blind, phase 3, randomised controlled study Xiaohong Fan, Xiahong Dai, Yun Ling, Lihua Wu, Lingling Tang, Chunxian Peng, et al. (+33)
23 [GO] 2023―Nov―22 UK Covid-19 Inquiry Talha Burki
24 [GO] 2023―Nov―22 Boost for COVID-19 testing in the USA Sanjeet Bagcchi
25 [GO] 2023―Nov―21 Coming to early conclusions during a pandemic Michael Boch, Patrick E Beeler, Balthasar L Hug, Sonja Bertschy
26 [GO] 2023―Nov―07 Virus isolation and neutralisation of SARS-CoV-2 variants BA.2.86 and EG.5.1 Ria Lassaunière, Charlotta Polacek, Magdalena Utko, Karina M Sørensen, Sharmin Baig, Kirsten Ellegaard, et al. (+18)
27 [GO] 2023―Oct―25 New licensing agreements for COVID-19 Timothy Jesudason
28 [GO] 2023―Oct―16 COVID-19 in the USA Sanjeet Bagcchi
29 [GO] 2023―Oct―06 Tracing the new SARS-CoV-2 variant BA.2.86 in the community through wastewater surveillance in Bangkok, Thailand Dhammika Leshan Wannigama, Mohan Amarasiri, Phatthranit Phattharapornjaroen, Cameron Hurst, Charin Modchang, Sudarat Chadsuthi, et al. (+32)
30 [GO] 2023―Sep―28 Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial William H K Schilling, Podjanee Jittamala, James A Watson, Simon Boyd, Viravarn Luvira, Tanaya Siripoon, et al. (+85)
31 [GO] 2023―Sep―27 Sensitivity of the SARS-CoV-2 BA.2.86 variant to prevailing neutralising antibody responses Daniel J Sheward, Yiqiu Yang, Michelle Westerberg, Sofia Öling, Sandra Muschiol, Kenta Sato, et al. (+4)
32 [GO] 2023―Sep―19 Antigenicity and infectivity characterisation of SARS-CoV-2 BA.2.86 Sijie Yang, Yuanling Yu, Fanchong Jian, Weiliang Song, Ayijiang Yisimayi, Xiaosu Chen, et al. (+15)
33 [GO] 2023―Sep―19 A pandemic playbook Vijay Shankar Balakrishnan
34 [GO] 2023―Sep―18 Transmissibility, infectivity, and immune evasion of the SARS-CoV-2 BA.2.86 variant Keiya Uriu, Jumpei Ito, Yusuke Kosugi, Yuri L Tanaka, Yuka Mugita, Ziyi Guo, et al. (+9)
35 [GO] 2023―Sep―13 SARS-CoV-2-related mortality decrease in nursing home residents given multiple COVID-19 boosters Kim Blom, Peter Fjällström, Christian Molnár, Mikael Åberg, Linnea Vikström, Julia Wigren-Byström, et al. (+6)
36 [GO] 2023―Sep―13 Neutralisation sensitivity of SARS-CoV-2 lineages EG.5.1 and XBB.2.3 Lu Zhang, Amy Kempf, Inga Nehlmeier, Anne Cossmann, Alexandra Dopfer-Jablonka, Metodi V Stankov, et al. (+5)
37 [GO] 2023―Sep―11 Antibody neutralisation of emerging SARS-CoV-2 subvariants: EG.5.1 and XBC.1.6 Qian Wang, Yicheng Guo, Richard M Zhang, Jerren Ho, Hiroshi Mohri, Riccardo Valdez, et al. (+4)
38 [GO] 2023―Sep―11 Antiviral efficacy of the SARS-CoV-2 XBB breakthrough infection sera against omicron subvariants including EG.5 Yu Kaku, Yusuke Kosugi, Keiya Uriu, Jumpei Ito, Alfredo A Hinay, Jin Kuramochi, et al. (+5)
39 [GO] 2023―Aug―21 Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial Bruno Maranda, Sébastien M Labbé, Magali Lurquin, Pascal Brabant, Alexandre Fugère, Jean-François Larrivée, et al. (+6)
40 [GO] 2023―Aug―21 The insights from SARS-CoV-2 antibody treatment for future emerging infectious diseases Yeming Wang, Bin Cao
41 [GO] 2023―Aug―09 COVID-19 pandemic: a catalyst for accelerating global action on patient safety Rebecca Grant, Daniel Benamouzig, Howard Catton, Vincent Chi-Chung Cheng, Neelam Dhingra, Ramanan Laxminarayan, et al. (+14)
42 [GO] 2023―Aug―02 Effectiveness of bivalent mRNA vaccines against medically attended symptomatic SARS-CoV-2 infection and COVID-19-related hospital admission among SARS-CoV-2-naive and previously infected individuals: a retrospective cohort study Celine Y Tan, Calvin J Chiew, Deanette Pang, Vernon J Lee, Benjamin Ong, Lin-Fa Wang, et al. (+3)
43 [GO] 2023―Jul―18 Relative effectiveness of monovalent and bivalent mRNA boosters in preventing severe COVID-19 due to omicron BA.5 infection up to 4 months post-administration in people aged 60 years or older in Italy: a retrospective matched cohort study Alberto Mateo-Urdiales, Chiara Sacco, Emmanouil Alexandros Fotakis, Martina Del Manso, Antonino Bella, Flavia Riccardo, et al. (+11)
44 [GO] 2023―Jul―18 Are bivalent vaccines better than ancestral-virus monovalent vaccines in protecting against severe omicron COVID-19? Shabir A Madhi, Daniel R Feikin
45 [GO] 2023―Jul―12 Duration of protection of ancestral-strain monovalent vaccines and effectiveness of bivalent BA.1 boosters against COVID-19 hospitalisation in England: a test-negative case-control study Freja Cordelia Møller Kirsebom, Nick Andrews, Julia Stowe, Mary Ramsay, Jamie Lopez Bernal
46 [GO] 2023―Jul―12 Effectiveness of monovalent and bivalent COVID-19 vaccines Thiago Cerqueira-Silva, Viviane S Boaventura, Manoel Barral-Netto
47 [GO] 2023―Jul―05 The importance of getting the ethics right in a pandemic treaty G Owen Schaefer, Caesar A Atuire, Sharon Kaur, Michael Parker, Govind Persad, Maxwell J Smith, et al. (+2)
48 [GO] 2023―Jun―30 Associations of COVID-19 symptoms with omicron subvariants BA.2 and BA.5, host status, and clinical outcomes in Japan: a registry-based observational study Sho Nakakubo, Naoki Kishida, Kenichi Okuda, Keisuke Kamada, Masami Iwama, Masaru Suzuki, et al. (+5)
49 [GO] 2023―Jun―30 The future of COVID-19 surveillance in Japan Shinya Tsuzuki
50 [GO] 2023―Jun―24 Sharing the road during the COVID-19 pandemic Henrietta Dunsmuir
51 [GO] 2023―Jun―24 A tale of two pandemics Sylvia Warren
52 [GO] 2023―Jun―20 Exploring the potential benefits of mucosal COVID-19 vaccines: opportunities and challenges Julio Croda
53 [GO] 2023―Jun―20 Safety, immunogenicity and protection of heterologous boost with an aerosolised Ad5-nCoV after two-dose inactivated COVID-19 vaccines in adults: a multicentre, open-label phase 3 trial Jing-Xin Li, Li-Hua Hou, Jin-Bo Gou, Zun-Dong Yin, Shi-Po Wu, Fu-Zhen Wang, et al. (+19)
54 [GO] 2023―Jun―20 Safety of COVID-19 booster dose: is the juice worth the squeeze? Shabir A Madhi, Alane Izu
55 [GO] 2023―Jun―20 Bivalent COVID-19 mRNA vaccine against omicron subvariants in immunocompromised patients Javier T Solera, Matthew Ierullo, Berta G Arbol, Faranak Mavandadnejad, Alexandra Kurtesi, Freda Qi, et al. (+5)
56 [GO] 2023―Jun―20 Safety of monovalent and bivalent BNT162b2 mRNA COVID-19 vaccine boosters in at-risk populations in Israel: a large-scale, retrospective, self-controlled case series study Dan Yamin, Matan Yechezkel, Ronen Arbel, Tanya Beckenstein, Ruslan Sergienko, Hadar Duskin-Bitan, et al. (+4)
57 [GO] 2023―Jun―19 Omicron BA.1-containing mRNA-1273 boosters compared with the original COVID-19 vaccine in the UK: a randomised, observer-blind, active-controlled trial Ivan T Lee, Catherine A Cosgrove, Patrick Moore, Claire Bethune, Rhiannon Nally, Marcin Bula, et al. (+60)
58 [GO] 2023―Jun―19 Adapted vaccine strategy: facing the persistent challenges of COVID-19 Lianhan Shang, Bin Cao
59 [GO] 2023―Jun―16 Effects of COVID-19 vaccination and previous SARS-CoV-2 infection on omicron infection and severe outcomes in children under 12 years of age in the USA: an observational cohort study Dan-Yu Lin, Yangjianchen Xu, Yu Gu, Donglin Zeng, Bradford Wheeler, Hayley Young, et al. (+2)
60 [GO] 2023―Jun―08 Outpatient treatment of COVID-19 and incidence of post-COVID-19 condition over 10 months (COVID-OUT): a multicentre, randomised, quadruple-blind, parallel-group, phase 3 trial Carolyn T Bramante, John B Buse, David M Liebovitz, Jacinda M Nicklas, Michael A Puskarich, Ken Cohen, et al. (+25)
61 [GO] 2023―Jun―05 Opportunities and challenges of leveraging COVID-19 vaccine innovation and technologies for developing sustainable vaccine manufacturing capabilities in Africa Bavesh D Kana, Patrick Arbuthnot, Benjamin K Botwe, Yahya E Choonara, Fatima Hassan, Hechmi Louzir, et al. (+6)
62 [GO] 2023―Jun―05 Leveraging lessons from the COVID-19 pandemic to strengthen low-income and middle-income country preparedness for future global health threats Ayoade Alakija
63 [GO] 2023―Jun―05 How can lessons from the COVID-19 pandemic enhance antimicrobial resistance surveillance and stewardship? Kamini Walia, Marc Mendelson, Gagandeep Kang, Ramasubramanian Venkatasubramanian, Rina Sinha, Sonam Vijay, et al. (+8)
64 [GO] 2023―Jun―05 Leveraging the positives from the pandemic to strengthen infectious disease care in low-income and middle-income countries Boghuma K Titanji, Madhukar Pai
65 [GO] 2023―May―26 How to survive to the COVID-19 pandemic Georgia Bisbas
66 [GO] 2023―May―19 CS-2034 mRNA vaccine: a new option for COVID-19 infection? Ruiqi Zhang, Ivan Fan-Ngai Hung
67 [GO] 2023―May―04 Lessons from COVID-19 for rescalable data collection Sangeeta Bhatia, Natsuko Imai, Oliver J Watson, Auss Abbood, Philip Abdelmalik, Thijs Cornelissen, et al. (+9)
68 [GO] 2023―May―03 Virological characteristics of the SARS-CoV-2 omicron XBB.1.16 variant Daichi Yamasoba, Keiya Uriu, Arnon Plianchaisuk, Yusuke Kosugi, Lin Pan, Jiri Zahradnik, et al. (+2)
69 [GO] 2023―May―01 All-cause and pathogen-specific lower respiratory tract infection hospital admissions in children younger than 5 years during the COVID-19 pandemic (2020-22) compared with the pre-pandemic period (2015-19) in South Africa: an observational study Alane Izu, Marta C Nunes, Fatima Solomon, Vicky Baillie, Natali Serafin, Charl Verwey, et al. (+6)
70 [GO] 2023―May―01 Infectious diseases in the COVID-19 era: gaps between countries Corinne Levy, Robert Cohen
71 [GO] 2023―Apr―26 COVID-19 in India's northeast Genevieve Pascal
72 [GO] 2023―Apr―26 More data needed on efficacy and safety of monovalent vaccines against SARS-CoV-2 omicron variants Paul A Monach, Westyn Branch-Elliman
73 [GO] 2023―Apr―21 Bivalent omicron (BA.1) booster vaccination against SARS-CoV-2 Andrey V Vasin, Marina A Stukova
74 [GO] 2023―Apr―14 Effectiveness of a bivalent mRNA vaccine booster dose to prevent severe COVID-19 outcomes: a retrospective cohort study Ronen Arbel, Alon Peretz, Ruslan Sergienko, Michael Friger, Tanya Beckenstein, Hadar Duskin-Bitan, et al. (+4)
75 [GO] 2023―Apr―14 Effectiveness of bivalent mRNA booster vaccines against COVID-19: methodological and public health considerations Anna Stoliaroff-Pepin, Thomas Harder
76 [GO] 2023―Mar―29 SARS-CoV-2 neutralising antibodies after bivalent versus monovalent booster Qian Wang, Anthony Bowen, Anthony R Tam, Riccardo Valdez, Emily Stoneman, Ian A Mellis, et al. (+3)
77 [GO] 2023―Mar―28 Performance of antigen lateral flow devices in the UK during the alpha, delta, and omicron waves of the SARS-CoV-2 pandemic: a diagnostic and observational study David W Eyre, Matthias Futschik, Sarah Tunkel, Jia Wei, Joanna Cole-Hamilton, Rida Saquib, et al. (+10)
78 [GO] 2023―Mar―28 The performance of rapid antigen tests against SARS-CoV-2 variants Jacqueline Prestedge, Deborah A Williamson
79 [GO] 2023―Mar―22 Pandemic policy and the ethics of elimination Euzebiusz Jamrozik
80 [GO] 2023―Mar―15 Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system Joseph A Lewnard, John M McLaughlin, Debbie Malden, Vennis Hong, Laura Puzniak, Bradley K Ackerson, et al. (+6)
81 [GO] 2023―Mar―13 Protective immunity of SARS-CoV-2 infection and vaccines against medically attended symptomatic omicron BA.4, BA.5, and XBB reinfections in Singapore: a national cohort study Celine Y Tan, Calvin J Chiew, Deanette Pang, Vernon J Lee, Benjamin Ong, David Chien Lye, Kelvin Bryan Tan
82 [GO] 2023―Mar―10 Long-term COVID-19 booster effectiveness by infection history and clinical vulnerability and immune imprinting: a retrospective population-based cohort study Hiam Chemaitelly, Houssein H Ayoub, Patrick Tang, Peter Coyle, Hadi M Yassine, Asmaa A Al Thani, et al. (+18)
83 [GO] 2023―Mar―07 Efficacy of antivirals and bivalent mRNA vaccines against SARS-CoV-2 isolate CH.1.1 Ryuta Uraki, Mutsumi Ito, Maki Kiso, Seiya Yamayoshi, Kiyoko Iwatsuki-Horimoto, Yuko Sakai-Tagawa, et al. (+13)
84 [GO] 2023―Mar―07 Being ready for the next influenza pandemic? Thijs Kuiken, Ron A M Fouchier, Marion P G Koopmans
85 [GO] 2023―Feb―22 Alemka Markotić-from hantavirus to COVID-19 Tony Kirby
86 [GO] 2023―Feb―13 Viral burden rebound in hospitalised patients with COVID-19 receiving oral antivirals in Hong Kong: a population-wide retrospective cohort study Carlos K H Wong, Kristy T K Lau, Ivan C H Au, Eric H Y Lau, Leo L M Poon, Ivan F N Hung, et al. (+2)
87 [GO] 2023―Feb―13 SARS-CoV-2 rebound with and without antivirals Nicola Petrosillo
88 [GO] 2023―Feb―11 Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study Neil R Aggarwal, Kyle C Molina, Laurel E Beaty, Tellen D Bennett, Nichole E Carlson, David A Mayer, et al. (+4)
89 [GO] 2023―Feb―10 Real-world effectiveness of nirmatrelvir-ritonavir against BA.4 and BA.5 omicron SARS-CoV-2 variants Carlos K H Wong, Kristy T K Lau, Gabriel M Leung
90 [GO] 2023―Feb―01 Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant Keiya Uriu, Jumpei Ito, Jiri Zahradnik, Shigeru Fujita, Yusuke Kosugi, Gideon Schreiber, Kei Sato
91 [GO] 2023―Feb―01 BNT162b2 antigen dose and SARS-CoV-2 omicron infection in adolescents Hiam Chemaitelly, Houssein H Ayoub, Peter Coyle, Patrick Tang, Hadi M Yassine, Asmaa A Al Thani, et al. (+17)
92 [GO] 2023―Jan―30 COVID-19 travel policies for people from China and discrimination Guiqing He, Jeffery A Jones, Wenjie Sun
93 [GO] 2023―Jan―30 Recalling ancestral SARS-CoV-2 variants: is it an original sin with benefits? Sebastian Hoehl, Sandra Ciesek
94 [GO] 2023―Jan―28 Efficacy and safety of antimicrobial stewardship prospective audit and feedback in patients hospitalised with COVID-19 (COVASP): a pragmatic, cluster-randomised, non-inferiority trial Justin Z Chen, Holly L Hoang, Maryna Yaskina, Dima Kabbani, Karen E Doucette, Stephanie W Smith, et al. (+7)
95 [GO] 2023―Jan―28 Too many antibiotics for patients with COVID-19 despite low bacterial infections Daniele Roberto Giacobbe, Matteo Bassetti
96 [GO] 2023―Jan―26 The end of the mpox pandemic? Talha Burki
97 [GO] 2023―Jan―18 Protective effectiveness of previous SARS-CoV-2 infection and hybrid immunity against the omicron variant and severe disease: a systematic review and meta-regression Niklas Bobrovitz, Harriet Ware, Xiaomeng Ma, Zihan Li, Reza Hosseini, Christian Cao, et al. (+16)
98 [GO] 2023―Jan―18 The benefit of vaccination after previous SARS-CoV-2 infection in the omicron era Viviane S Boaventura, Thiago Cerqueira-Silva, Manoel Barral-Netto
99 [GO] 2023―Jan―11 Immunogenicity and safety in healthy adults of full dose versus half doses of COVID-19 vaccine (ChAdOx1-S or BNT162b2) or full-dose CoronaVac administered as a booster dose after priming with CoronaVac: a randomised, observer-masked, controlled trial in Indonesia Eddy Fadlyana, Djatnika Setiabudi, C B Kartasasmita, Nina Dwi Putri, Sri Rezeki Hadinegoro, Kim Mulholland, et al. (+18)
100 [GO] 2023―Jan―11 7-month duration of SARS-CoV-2 mucosal immunoglobulin-A responses and protection Ulrika Marking, Oscar Bladh, Sebastian Havervall, Julia Svensson, Nina Greilert-Norin, Katherina Aguilera, et al. (+13)
101 [GO] 2023―Jan―11 Tracking immune correlates of protection for emerging SARS-CoV-2 variants Eric J Nilles, Cecilia Then Paulino, Michael de St Aubin, William Duke, Petr Jarolim, Isaac Miguel Sanchez, et al. (+6)
102 [GO] 2023―Jan―05 Neutralisation sensitivity of the SARS-CoV-2 XBB.1 lineage Prerna Arora, Anne Cossmann, Sebastian R Schulz, Gema Morillas Ramos, Metodi V Stankov, Hans-Martin Jäck, et al. (+3)
103 [GO] 2022―Dec―21 COVID-19 in the MENA region Aula Abbara
104 [GO] 2022―Dec―21 Race, inequalities, and burden of COVID-19 in the USA Georgia Bisbas
105 [GO] 2022―Dec―12 Effectiveness of BNT162b2 and CoronaVac COVID-19 vaccination against asymptomatic and symptomatic infection of SARS-CoV-2 omicron BA.2 in Hong Kong: a prospective cohort study Nicole Ngai Yung Tsang, Hau Chi So, Benjamin J Cowling, Gabriel M Leung, Dennis Kai Ming Ip
106 [GO] 2022―Dec―07 Antibiotic prescribing in general practice during COVID-19 and beyond Olivia K Bryant, Kenneth K C Man, Yogini H Jani, Ian C K Wong, Wallis C Y Lau
107 [GO] 2022―Dec―02 Decline of RSV-specific antibodies during the COVID-19 pandemic Gerco den Hartog, Puck B van Kasteren, Rutger M Schepp, Anne C Teirlinck, Fiona R M van der Klis, Robert S van Binnendijk
108 [GO] 2022―Nov―25 Considerations of hybrid immunity and the future of adolescent COVID-19 vaccination Stephanie A Irving, Sarah A Buchan
109 [GO] 2022―Nov―25 Protection against symptomatic infection with delta (B.1.617.2) and omicron (B.1.1.529) BA.1 and BA.2 SARS-CoV-2 variants after previous infection and vaccination in adolescents in England, August, 2021-March, 2022: a national, observational, test-negative, case-control study Annabel A Powell, Freja Kirsebom, Julia Stowe, Mary E Ramsay, Jamie Lopez-Bernal, Nick Andrews, Shamez N Ladhani
110 [GO] 2022―Nov―24 The sound of waves: tracking the pandemic Tri-Long Nguyen, Mads Kamper-Jørgensen
111 [GO] 2022―Nov―01 The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages Prerna Arora, Lu Zhang, Inga Nehlmeier, Amy Kempf, Anne Cossmann, Alexandra Dopfer-Jablonka, et al. (+5)
112 [GO] 2022―Nov―01 Impact of COVID-19 measures in rural South Africa Kitty Graham
113 [GO] 2022―Oct―31 Resistance of SARS-CoV-2 omicron subvariant BA.4.6 to antibody neutralisation Qian Wang, Zhiteng Li, Jerren Ho, Yicheng Guo, Andre Yanchen Yeh, Hiroshi Mohri, et al. (+11)
114 [GO] 2022―Oct―27 Alternative strategies to increase the immunogenicity of COVID-19 vaccines in kidney transplant recipients not responding to two or three doses of an mRNA vaccine (RECOVAC): a randomised clinical trial Marcia M L Kho, A Lianne Messchendorp, Sophie C Frölke, Celine Imhof, Vera JCH Koomen, S Reshwan K Malahe, et al. (+35)
115 [GO] 2022―Oct―27 SARS-CoV-2 vaccine strategies in kidney transplant recipients Maria Prendecki, Michelle Willicombe
116 [GO] 2022―Oct―25 BNT162b2 vaccine effectiveness against SARS-CoV-2 omicron BA.4 and BA.5 Sara Y Tartof, Jeff M Slezak, Laura Puzniak, Vennis Hong, Timothy B Frankland, Bradley K Ackerson, et al. (+6)
117 [GO] 2022―Oct―20 Durability of ChAdOx1 nCoV-19 (AZD1222) vaccine and hybrid humoral immunity against variants including omicron BA.1 and BA.4 6 months after vaccination (COV005): a post-hoc analysis of a randomised, phase 1b-2a trial Shabir A Madhi, Gaurav Kwatra, Simone I Richardson, Anthonet L Koen, Vicky Baillie, Clare L Cutland, et al. (+31)
118 [GO] 2022―Oct―19 Molnupiravir versus placebo in unvaccinated and vaccinated patients with early SARS-CoV-2 infection in the UK (AGILE CST-2): a randomised, placebo-controlled, double-blind, phase 2 trial Saye H Khoo, Richard FitzGerald, Geoffrey Saunders, Calley Middleton, Shazaad Ahmad, Christopher J Edwards, et al. (+84)
119 [GO] 2022―Sep―29 Effectiveness of primary series and booster vaccination against SARS-CoV-2 infection and hospitalisation among adolescents aged 12-17 years in Singapore: a national cohort study Calvin J Chiew, M Premikha, Chia Yin Chong, Wycliffe E Wei, Benjamin Ong, David Chien Lye, et al. (+3)
120 [GO] 2022―Sep―27 Further humoral immunity evasion of emerging SARS-CoV-2 BA.4 and BA.5 subvariants Fanchong Jian, Yuanling Yu, Weiliang Song, Ayijiang Yisimayi, Lingling Yu, Yuxue Gao, et al. (+9)
121 [GO] 2022―Sep―26 Bebtelovimab: considerations for global access to treatments during a rapidly evolving pandemic Russell M Nichols, Carmen Deveau, Himanshu Upadhyaya
122 [GO] 2022―Sep―21 Dr Hammond's COVID-19 inquiry Peter Ranscombe
123 [GO] 2022―Sep―21 Hybrid immunity and strategies for COVID-19 vaccination David S Hui
124 [GO] 2022―Sep―21 Protection against omicron (B.1.1.529) BA.2 reinfection conferred by primary omicron BA.1 or pre-omicron SARS-CoV-2 infection among health-care workers with and without mRNA vaccination: a test-negative case-control study Sara Carazo, Danuta M Skowronski, Marc Brisson, Sapha Barkati, Chantal Sauvageau, Nicholas Brousseau, et al. (+9)
125 [GO] 2022―Sep―13 Efficacy, safety, and immunogenicity of a booster regimen of Ad26.COV2.S vaccine against COVID-19 (ENSEMBLE2): results of a randomised, double-blind, placebo-controlled, phase 3 trial Karin Hardt, An Vandebosch, Jerald Sadoff, Mathieu Le Gars, Carla Truyers, David Lowson, et al. (+282)
126 [GO] 2022―Sep―09 COVID-19 vaccination protects children and adolescents Stephanie A Irving, Nicola P Klein
127 [GO] 2022―Sep―09 Initial protection against SARS-CoV-2 omicron lineage infection in children and adolescents by BNT162b2 in Israel: an observational study Ofra Amir, Yair Goldberg, Micha Mandel, Yinon M Bar-On, Omri Bodenheimer, Laurence Freedman, et al. (+4)
128 [GO] 2022―Sep―06 Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial Rajeka Lazarus, Benedicte Querton, Irena Corbic Ramljak, Shailesh Dewasthaly, Juan Carlos Jaramillo, Katrin Dubischar, et al. (+35)
129 [GO] 2022―Sep―06 Evaluating novel COVID-19 vaccines in the current chapter of the pandemic Corine H GeurtsvanKessel, Rory D de Vries
130 [GO] 2022―Sep―06 Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage Henning Gruell, Kanika Vanshylla, Pinkus Tober-Lau, David Hillus, Leif Erik Sander, Florian Kurth, Florian Klein
131 [GO] 2022―Sep―02 Epidemiology of respiratory syncytial virus in children younger than 5 years in England during the COVID-19 pandemic, measured by laboratory, clinical, and syndromic surveillance: a retrospective observational study Megan Bardsley, Roger A Morbey, Helen E Hughes, Charles R Beck, Conall H Watson, Hongxin Zhao, et al. (+3)
132 [GO] 2022―Sep―02 Quantifying the RSV immunity debt following COVID-19: a public health matter Marie-Noëlle Billard, Louis J Bont
133 [GO] 2022―Aug―31 The Johns Hopkins University Center for Systems Science and Engineering COVID-19 Dashboard: data collection process, challenges faced, and lessons learned Ensheng Dong, Jeremy Ratcliff, Tamara D Goyea, Aaron Katz, Ryan Lau, Timothy K Ng, et al. (+12)
134 [GO] 2022―Aug―31 Tackling the politicisation of COVID-19 data reporting through open access data sharing Chad R Wells, Alison P Galvani
135 [GO] 2022―Aug―26 Beneficial non-specific effects of live vaccines against COVID-19 and other unrelated infections Peter Aaby, Mihai G Netea, Christine S Benn
136 [GO] 2022―Aug―26 Persistence, prevalence, and polymorphism of sequelae after COVID-19 in unvaccinated, young adults of the Swiss Armed Forces: a longitudinal, cohort study (LoCoMo) Jeremy Werner Deuel, Elisa Lauria, Thibault Lovey, Sandrine Zweifel, Mara Isabella Meier, Roland Züst, et al. (+3)
137 [GO] 2022―Aug―26 COVID-19 sequelae: can long-term effects be predicted? Eleni Gavriilaki, Styliani Kokoris
138 [GO] 2022―Aug―26 Home as the new frontier for the treatment of COVID-19: the case for anti-inflammatory agents Norberto Perico, Monica Cortinovis, Fredy Suter, Giuseppe Remuzzi
139 [GO] 2022―Aug―24 Early oral antiviral use in patients hospitalised with COVID-19 Dorota Zarębska-Michaluk, Robert Flisiak
140 [GO] 2022―Aug―24 Real-world effectiveness of early molnupiravir or nirmatrelvir-ritonavir in hospitalised patients with COVID-19 without supplemental oxygen requirement on admission during Hong Kong's omicron BA.2 wave: a retrospective cohort study Carlos K H Wong, Ivan C H Au, Kristy T K Lau, Eric H Y Lau, Benjamin J Cowling, Gabriel M Leung
141 [GO] 2022―Aug―24 Ximena Aguilera-guiding pandemic preparedness in Chile Tony Kirby
142 [GO] 2022―Aug―23 Variation in reported SARS-CoV-2 cases after testing policy changes Florence Halford, Sophie Nash, Elise Tessier, Meaghan Kall, Gavin Dabrera
143 [GO] 2022―Aug―22 Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state Jeremy Samuel Faust, Benjamin Renton, Alexander Junxiang Chen, Chengan Du, Chenxue Liang, Shu-Xia Li, et al. (+2)
144 [GO] 2022―Aug―16 The growing threat of wild poliovirus 1 and vaccine-derived cases in the COVID-19 era Carlos Franco-Paredes, Alfonso J Rodriguez-Morales, Andrés F Henao-Martínez, Peter Carrasco, Jose Tuells
145 [GO] 2022―Aug―11 Safety of mRNA COVID-19 vaccines during pregnancy Sascha Ellington, Christine K Olson
146 [GO] 2022―Aug―11 Safety of COVID-19 vaccines in pregnancy: a Canadian National Vaccine Safety (CANVAS) network cohort study Manish Sadarangani, Phyumar Soe, Hennady P Shulha, Louis Valiquette, Otto G Vanderkooi, James D Kellner, et al. (+8)
147 [GO] 2022―Aug―10 Safety and immunogenicity following a homologous booster dose of a SARS-CoV-2 recombinant spike protein vaccine (NVX-CoV2373): a secondary analysis of a randomised, placebo-controlled, phase 2 trial Raburn M Mallory, Neil Formica, Susan Pfeiffer, Bethanie Wilkinson, Alex Marcheschi, Gary Albert, et al. (+36)
148 [GO] 2022―Aug―09 Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative case-control study Pilar T V Florentino, Tristan Millington, Thiago Cerqueira-Silva, Chris Robertson, Vinicius de Araújo Oliveira, Juracy B S Júnior, et al. (+17)
149 [GO] 2022―Aug―04 Maintaining genomic surveillance using whole-genome sequencing of SARS-CoV-2 from rapid antigen test devices Genevieve E Martin, George Taiaroa, Mona L Taouk, Ivana Savic, Jacinta O'Keefe, Robert Quach, et al. (+4)
150 [GO] 2022―Jul―20 Pandemic diaries under the lens Vijay Shankar Balakrishnan
151 [GO] 2022―Jul―15 Vaccine effectiveness of one, two, and three doses of BNT162b2 and CoronaVac against COVID-19 in Hong Kong: a population-based observational study Martina E McMenamin, Joshua Nealon, Yun Lin, Jessica Y Wong, Justin K Cheung, Eric H Y Lau, et al. (+3)
152 [GO] 2022―Jul―14 Paxlovid in patients who are immunocompromised and hospitalised with SARS-CoV-2 infection Fangfang Sun, Yanwei Lin, Xiaodong Wang, Yuan Gao, Shuang Ye
153 [GO] 2022―Jul―05 Efficacy and safety of a single dose of casirivimab and imdevimab for the prevention of COVID-19 over an 8-month period: a randomised, double-blind, placebo-controlled trial Gary A Herman, Meagan P O'Brien, Eduardo Forleo-Neto, Neena Sarkar, Flonza Isa, Peijie Hou, et al. (+257)
154 [GO] 2022―Jul―05 Stewardship of COVID-19 volunteers by nested trial design Robert L Gottlieb, Raymund R Razonable
155 [GO] 2022―Jul―05 Monoclonal antibody therapies against SARS-CoV-2 Daniele Focosi, Scott McConnell, Arturo Casadevall, Emiliano Cappello, Giulia Valdiserra, Marco Tuccori
156 [GO] 2022―Jun―24 COVID-19 vaccinations for children Abdul Razak Mariatulqabtiah, Karen R Buttigieg
157 [GO] 2022―Jun―23 The global impact of disproportionate vaccination coverage on COVID-19 mortality Chad R Wells, Alison P Galvani
158 [GO] 2022―Jun―23 Global impact of the first year of COVID-19 vaccination: a mathematical modelling study Oliver J Watson, Gregory Barnsley, Jaspreet Toor, Alexandra B Hogan, Peter Winskill, Azra C Ghani
159 [GO] 2022―Jun―22 Duration of effectiveness of vaccination against COVID-19 caused by the omicron variant Melissa M Higdon, Anurima Baidya, Karoline K Walter, Minal K Patel, Hanane Issa, Emmanuelle Espié, et al. (+2)
160 [GO] 2022―Jun―22 COVID-19, haemophagocytic lymphohistiocytosis, and infection-induced cytokine storm syndromes Caroline Spaner, Mariam Goubran, Audi Setiadi, Luke Y C Chen
161 [GO] 2022―Jun―22 2 years of the Access to COVID-19 Tools-Accelerator Vijay Shankar Balakrishnan
162 [GO] 2022―Jun―16 Immunogenicity and reactogenicity of an inactivated SARS-CoV-2 vaccine (BBV152) in children aged 2-18 years: interim data from an open-label, non-randomised, age de-escalation phase 2/3 study Krishna Mohan Vadrevu, Siddharth Reddy, Harsh Jogdand, Brunda Ganneru, Nizam Mirza, Virendra Nath Tripathy, et al. (+8)
163 [GO] 2022―Jun―10 Immune responses after omicron infection in triple-vaccinated health-care workers with and without previous SARS-CoV-2 infection Kim Blom, Ulrika Marking, Sebastian Havervall, Nina Greilert Norin, Max Gordon, Marina García, et al. (+10)
164 [GO] 2022―Jun―09 Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies Daichi Yamasoba, Yusuke Kosugi, Izumi Kimura, Shigeru Fujita, Keiya Uriu, Jumpei Ito, Kei Sato
165 [GO] 2022―Jun―02 FIND documents dramatic reduction in COVID-19 testing Ann Danaiya Usher
166 [GO] 2022―Jun―02 Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study Susana Monge, Ayelén Rojas-Benedicto, Carmen Olmedo, Clara Mazagatos, María José Sierra, Aurora Limia, et al. (+49)
167 [GO] 2022―May―25 Final results of the DisCoVeRy trial of remdesivir for patients admitted to hospital with COVID-19 Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, France Mentré, Charles Burdet, et al. (+166)
168 [GO] 2022―May―25 Additional considerations for assessing COVID-19 impact on dengue transmission Christina Yek, Andrea R Pacheco, Chanthap Lon, Rithea Leang, Jessica E Manning
169 [GO] 2022―May―25 Additional considerations for assessing COVID-19 impact on dengue transmission - Authors' reply Oliver J Brady, Huaiyu Tian
170 [GO] 2022―May―24 COVID-19 vaccine effectiveness against the omicron (BA.2) variant in England Freja C M Kirsebom, Nick Andrews, Julia Stowe, Samuel Toffa, Ruchira Sachdeva, Eileen Gallagher, et al. (+5)
171 [GO] 2022―May―13 Risk of arterial and venous thromboses after COVID-19 William Whiteley, Angela Wood
172 [GO] 2022―May―13 Venous or arterial thrombosis and deaths among COVID-19 cases: a European network cohort study Edward Burn, Talita Duarte-Salles, Sergio Fernandez-Bertolin, Carlen Reyes, Kristin Kostka, Antonella Delmestri, et al. (+3)
173 [GO] 2022―May―09 Safety, immunogenicity, and reactogenicity of BNT162b2 and mRNA-1273 COVID-19 vaccines given as fourth-dose boosters following two doses of ChAdOx1 nCoV-19 or BNT162b2 and a third dose of BNT162b2 (COV-BOOST): a multicentre, blinded, phase 2, randomised trial Alasdair P S Munro, Shuo Feng, Leila Janani, Victoria Cornelius, Parvinder K Aley, Gavin Babbage, et al. (+358)
174 [GO] 2022―May―09 What a second booster dose of mRNA COVID-19 vaccines tells us Paul Loubet, Odile Launay
175 [GO] 2022―Apr―22 Implications of COVID-19 vaccine effectiveness waning for public health Anna Odone, Giacomo Pietro Vigezzi, Fausto Baldanti
176 [GO] 2022―Apr―22 Sustainability of surveillance systems for SARS-CoV-2 Cornelia Adlhoch, Helena de Carvalho Gomes
177 [GO] 2022―Apr―22 Risk of hospitalisation associated with infection with SARS-CoV-2 omicron variant versus delta variant in Denmark: an observational cohort study Peter Bager, Jan Wohlfahrt, Samir Bhatt, Marc Stegger, Rebecca Legarth, Camilla Holten Møller, et al. (+41)
178 [GO] 2022―Apr―21 Marion Koopmans-preparing for the next pandemic Tony Kirby
179 [GO] 2022―Apr―18 Impact of previous exposure to SARS-CoV-2 and of S-Trimer (SCB-2019) COVID-19 vaccination on the risk of reinfection: a randomised, double-blinded, placebo-controlled, phase 2 and 3 trial Igor Smolenov, Htay Htay Han, Ping Li, Carmen Baccarini, Carole Verhoeven, Frank Rockhold, et al. (+6)
180 [GO] 2022―Apr―18 The S-Trimer (SCB-2019) COVID-19 vaccine and reinfection with SARS-CoV-2 Jing-Xin Li, Feng-Cai Zhu
181 [GO] 2022―Apr―14 A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland Elsa Lorthe, Mathilde Bellon, Julie Berthelot, Grégoire Michielin, Arnaud G L'Huillier, Klara M Posfay-Barbe, et al. (+5)
182 [GO] 2022―Apr―13 Defining the determinants of vaccine uptake and undervaccination in migrant populations in Europe to improve routine and COVID-19 vaccine uptake: a systematic review Alison F Crawshaw, Yasmin Farah, Anna Deal, Kieran Rustage, Sally E Hayward, Jessica Carter, et al. (+8)
183 [GO] 2022―Apr―12 Comparable neutralisation evasion of SARS-CoV-2 omicron subvariants BA.1, BA.2, and BA.3 Prerna Arora, Lu Zhang, Cheila Rocha, Anzhalika Sidarovich, Amy Kempf, Sebastian Schulz, et al. (+12)
184 [GO] 2022―Apr―08 COVID-19 vaccine waning and effectiveness and side-effects of boosters: a prospective community study from the ZOE COVID Study Cristina Menni, Anna May, Lorenzo Polidori, Panayiotis Louca, Jonathan Wolf, Joan Capdevila, et al. (+5)
185 [GO] 2022―Apr―04 Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India Valliappan Muthu, Ritesh Agarwal, Atul Patel, Soundappan Kathirvel, Ooriapadickal Cherian Abraham, Ashutosh Nath Aggarwal, et al. (+21)
186 [GO] 2022―Apr―01 Interplay of infection and vaccination in long-term protection from COVID-19 Hyon-Xhi Tan, Jennifer A Juno
187 [GO] 2022―Apr―01 Risk of SARS-CoV-2 reinfection and COVID-19 hospitalisation in individuals with natural and hybrid immunity: a retrospective, total population cohort study in Sweden Peter Nordström, Marcel Ballin, Anna Nordström
188 [GO] 2022―Apr―01 Modelling results on the impact of COVID-19 testing in schools Louise Dyson
189 [GO] 2022―Apr―01 Screening and vaccination against COVID-19 to minimise school closure: a modelling study Elisabetta Colosi, Giulia Bassignana, Diego Andrés Contreras, Canelle Poirier, Pierre-Yves Boëlle, Simon Cauchemez, et al. (+5)
190 [GO] 2022―Apr―01 Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26.COV2.S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative, case-control study Thiago Cerqueira-Silva, Jason R Andrews, Viviane S Boaventura, Otavio T Ranzani, Vinicius de Araújo Oliveira, Enny S Paixão, et al. (+14)
191 [GO] 2022―Apr―01 Effectiveness of SARS-CoV-2 vaccines in the post-natural infection world Pramod Kumar Garg, Ramachandran Thiruvengadam
192 [GO] 2022―Mar―29 Availability of oral antivirals against SARS-CoV-2 infection and the requirement for an ethical prescribing approach Rafael Dal-Ré, Sören L Becker, Emmanuel Bottieau, Søren Holm
193 [GO] 2022―Mar―24 Hong Kong's fifth COVID-19 wave-the worst yet Talha Burki
194 [GO] 2022―Mar―24 Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India - Authors' reply Ramachandran Thiruvengadam, Amit Awasthi, Shinjini Bhatnagar, Pramod Kumar Garg
195 [GO] 2022―Mar―24 Kanta Subbarao-confronting influenza and COVID-19 Tony Kirby
196 [GO] 2022―Mar―24 Effectiveness of ChAdOx1 nCoV-19 vaccine during the delta (B.1.617.2) variant surge in India Sasanka Chakrabarti, Sankha Shubhra Chakrabarti, Gourav Chandan, Upinder Kaur, Bimal Kumar Agrawal
197 [GO] 2022―Mar―21 Effectiveness of BNT162b2 against COVID-19 in adolescents Annabel A Powell, Freja Kirsebom, Julia Stowe, Kelsey McOwat, Vanessa Saliba, Mary E Ramsay, et al. (+3)
198 [GO] 2022―Mar―17 Neutralisation sensitivity of the SARS-CoV-2 omicron (B.1.1.529) variant: a cross-sectional study Daniel J Sheward, Changil Kim, Roy A Ehling, Alec Pankow, Xaquin Castro Dopico, Robert Dyrdak, et al. (+6)
199 [GO] 2022―Mar―15 SARS-CoV-2 incidence, transmission, and reinfection in a rural and an urban setting: results of the PHIRST-C cohort study, South Africa, 2020-21 Cheryl Cohen, Jackie Kleynhans, Anne von Gottberg, Meredith L McMorrow, Nicole Wolter, Jinal N Bhiman, et al. (+38)
200 [GO] 2022―Mar―15 SARS-CoV-2 transmission: time to rethink public health strategy Arifa Parker, Halima Dawood
201 [GO] 2022―Mar―11 CD24Fc: an emerging COVID-19 therapy Christina M Eckhardt, Max R O'Donnell
202 [GO] 2022―Mar―11 Efficacy and safety of CD24Fc in hospitalised patients with COVID-19: a randomised, double-blind, placebo-controlled, phase 3 study James Welker, Juan D Pulido, Andrew T Catanzaro, Carlos D Malvestutto, Zihai Li, Jonathan B Cohen, et al. (+120)
203 [GO] 2022―Mar―09 Emerging evidence on heterologous COVID-19 vaccine schedules-To mix or not to mix? Edward P K Parker, Shalini Desai, Melanie Marti, Katherine L O'Brien, David C Kaslow, Sonali Kochhar, et al. (+5)
204 [GO] 2022―Mar―07 COVID-19 mRNA vaccine safety during the first 6 months of roll-out in the USA Matthew S Krantz, Elizabeth J Phillips
205 [GO] 2022―Mar―07 Safety of mRNA vaccines administered during the initial 6 months of the US COVID-19 vaccination programme: an observational study of reports to the Vaccine Adverse Event Reporting System and v-safe Hannah G Rosenblum, Julianne Gee, Ruiling Liu, Paige L Marquez, Bicheng Zhang, Penelope Strid, et al. (+8)
206 [GO] 2022―Mar―03 Measuring the effects of COVID-19-related disruption on dengue transmission in southeast Asia and Latin America: a statistical modelling study Yuyang Chen, Naizhe Li, José Lourenço, Lin Wang, Bernard Cazelles, Lu Dong, et al. (+53)
207 [GO] 2022―Mar―03 World Tuberculosis Day 2022: aligning COVID-19 and tuberculosis innovations to save lives and to end tuberculosis Francine Ntoumi, Jean B Nachega, Eleni Aklillu, Jeremiah Chakaya, Irina Felker, Farhana Amanullah, et al. (+3)
208 [GO] 2022―Mar―02 Movement dynamics: reduced dengue cases during the COVID-19 pandemic R Tedjo Sasmono, Marsha S Santoso
209 [GO] 2022―Feb―24 COVID-19 vaccine results might inform malaria vaccine strategies Movin Abeywickrema, Anna L Goodman
210 [GO] 2022―Feb―23 Education services in crisis due to COVID-19 Talha Burki
211 [GO] 2022―Feb―23 Compromised periodontal status could increase mortality for patients with COVID-19 Shipra Gupta, Miina Saarikko, Andreas Pfützner, Ismo T Räisänen, Timo Sorsa
212 [GO] 2022―Feb―23 COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe Evelyn Depoortere, Stefanie Sowinski, Arjon van Hengel, Barbara Kerstiëns, Irene Norstedt
213 [GO] 2022―Feb―23 COVID-19 kick-starts a new era for clinical trials and pandemic preparedness in Europe Edit Szepessy, Peter Arlett, Fergus Sweeney, Karl Broich, Andrzej Jan Rys
214 [GO] 2022―Feb―23 Wolfgang Preiser-co-discoverer of SARS-CoV-2 variants Tony Kirby
215 [GO] 2022―Feb―15 Understanding how fast SARS-CoV-2 variants transmit from household studies Yang Yang, Eben Kenah
216 [GO] 2022―Feb―15 Generation time of the alpha and delta SARS-CoV-2 variants: an epidemiological analysis William S Hart, Elizabeth Miller, Nick J Andrews, Pauline Waight, Philip K Maini, Sebastian Funk, Robin N Thompson
217 [GO] 2022―Feb―10 Transitioning to endemicity with COVID-19 research The Lancet Infectious Diseases
218 [GO] 2022―Jan―28 Has the COVID-19 pandemic increased tuberculosis mortality? David W Dowdy
219 [GO] 2022―Jan―28 COVID-19 vaccine inequity, dependency, and production capability in low-income and middle-income countries: the case of Bangladesh Abdullah Mahmud-Al-Rafat, Benjamin Hewins, Adnan Mannan, David J Kelvin, Md Morsaline Billah
220 [GO] 2022―Jan―28 COVID-19 vaccine: what are we doing and what should we do? Marcello Candelli
221 [GO] 2022―Jan―28 Persistence of protection against SARS-CoV-2 clinical outcomes up to 9 months since vaccine completion: a retrospective observational analysis in Lombardy, Italy Giovanni Corrao, Matteo Franchi, Danilo Cereda, Francesco Bortolan, Alberto Zoli, Olivia Leoni, et al. (+10)
222 [GO] 2022―Jan―25 Safety and immunogenicity of an AS03-adjuvanted SARS-CoV-2 recombinant protein vaccine (CoV2 preS dTM) in healthy adults: interim findings from a phase 2, randomised, dose-finding, multicentre study Saranya Sridhar, Arnel Joaquin, Matthew I Bonaparte, Agustin Bueso, Anne-Laure Chabanon, Aiying Chen, et al. (+40)
223 [GO] 2022―Jan―14 The origin of SARS-CoV-2 variants of concern Talha Burki
224 [GO] 2022―Jan―13 Time for Africa to future-proof, starting with COVID-19 The Lancet Infectious Diseases
225 [GO] 2021―Dec―24 Time to knock monoclonal antibodies off the platform for patients hospitalised with COVID-19 Adrienne E Shapiro, Rachel A Bender Ignacio
226 [GO] 2021―Dec―24 Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial Wesley H. Self, Uriel Sandkovsky, Cavan S. Reilly, David M. Vock, Robert L. Gottlieb, Michael Mack, et al. (+641)
227 [GO] 2021―Dec―23 All-cause mortality during the COVID-19 pandemic in Chennai, India: an observational study Joseph A Lewnard, Ayesha Mahmud, Tejas Narayan, Brian Wahl, T S Selvavinayagam, Chandra Mohan B, Ramanan Laxminarayan
228 [GO] 2021―Dec―23 Mortality during the COVID-19 pandemic: the blind spots in statistics Ajith Kumar A K, Neha Mishra
229 [GO] 2021―Dec―23 Do health-care workers need a COVID-19 vaccine booster? Nicola Cirillo
230 [GO] 2021―Dec―23 COVID-19 vaccine mandates in Europe Talha Burki
231 [GO] 2021―Dec―23 Transmissibility of SARS-CoV-2 among fully vaccinated individuals Carlos Franco-Paredes
232 [GO] 2021―Dec―23 Transmissibility of SARS-CoV-2 among fully vaccinated individuals Humphrey H T Ko
233 [GO] 2021―Dec―23 Transmissibility of SARS-CoV-2 among fully vaccinated individuals Mirjam J Knol, Jantien A Backer, Hester E de Melker, Susan van den Hof, Brechje de Gier
234 [GO] 2021―Dec―23 Transmissibility of SARS-CoV-2 among fully vaccinated individuals - Authors' reply Ajit Lalvani, Seran Hakki, Anika Singanayagam, Jake Dunning, Jack L Barnett, Michael A Crone, et al. (+2)
235 [GO] 2021―Dec―23 Practical measures for SARS-CoV-2 infection prevention Tatsuya Fujikawa
236 [GO] 2021―Dec―23 Practical measures for SARS-CoV-2 infection prevention - Authors' reply Josep M Llibre, Raquel Martin-Iguacel, Boris Revollo
237 [GO] 2021―Dec―21 The European clinical research response to optimise treatment of patients with COVID-19: lessons learned, future perspective, and recommendations Herman Goossens, Lennie Derde, Peter Horby, Marc Bonten
238 [GO] 2021―Dec―09 Emerging SARS-CoV-2 variants: shooting the messenger The Lancet Infectious Diseases
239 [GO] 2021―Dec―08 Booster doses for inactivated COVID-19 vaccines: if, when, and for whom Julio Croda, Otavio T Ranzani
240 [GO] 2021―Nov―26 Prevention of SARS-CoV-2 transmission during a large, live, indoor gathering (SPRING): a non-inferiority, randomised, controlled trial Constance Delaugerre, Frantz Foissac, Hendy Abdoul, Guillaume Masson, Laure Choupeaux, Eric Dufour, et al. (+15)
241 [GO] 2021―Nov―25 COVID-19 vaccines in the age of the delta variant Adam K Wheatley, Jennifer A Juno
242 [GO] 2021―Nov―25 Effectiveness of ChAdOx1 nCoV-19 vaccine against SARS-CoV-2 infection during the delta (B.1.617.2) variant surge in India: a test-negative, case-control study and a mechanistic study of post-vaccination immune responses Ramachandran Thiruvengadam, Amit Awasthi, Guruprasad Medigeshi, Sankar Bhattacharya, Shailendra Mani, Sridhar Sivasubbu, et al. (+27)
243 [GO] 2021―Nov―24 Dismal global tuberculosis situation due to COVID-19 Sanjeet Bagcchi
244 [GO] 2021―Nov―24 Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b/3 trial Peter G Kremsner, Rodolfo Andrés Ahuad Guerrero, Eunate Arana-Arri, Gustavo Jose Aroca Martinez, Marc Bonten, Reynaldo Chandler, et al. (+171)
245 [GO] 2021―Nov―24 Global emergence of SARS-CoV-2 variants: new foresight needed for improved vaccine efficacy Pragya D Yadav, Sanjay Kumar
246 [GO] 2021―Nov―24 COVID-19 vaccine intentions in Australia Benjamin Edwards, Nicholas Biddle, Matthew Gray, Kate Sollis
247 [GO] 2021―Nov―24 COVID-19 vaccine intentions in Australia Kristen Pickles, Tessa Copp, Rachael H Dodd, Erin Cvejic, Holly Seale, Maryke S Steffens, et al. (+3)
248 [GO] 2021―Nov―23 SARS-CoV-2 delta variant: a persistent threat to the effectiveness of vaccines Ramachandran Thiruvengadam, Akshay Binayke, Amit Awasthi
249 [GO] 2021―Nov―23 Effectiveness of an inactivated virus-based SARS-CoV-2 vaccine, BBV152, in India: a test-negative, case-control study Devashish Desai, Adil Rashid Khan, Manish Soneja, Ankit Mittal, Shivdas Naik, Parul Kodan, et al. (+21)
250 [GO] 2021―Nov―10 Infection control in the intensive care unit: expert consensus statements for SARS-CoV-2 using a Delphi method Prashant Nasa, Elie Azoulay, Arunaloke Chakrabarti, Jigeeshu V Divatia, Ravi Jain, Camilla Rodrigues, et al. (+37)
251 [GO] 2021―Nov―08 Protective immunity after recovery from SARS-CoV-2 infection Noah Kojima, Jeffrey D Klausner
252 [GO] 2021―Nov―03 COVID-19 vaccination in pregnancy-number needed to vaccinate to avoid harm Laura A Magee, Peter von Dadelszen, Erkan Kalafat, Emma L Duncan, Pat O'Brien, Edward Morris, et al. (+2)
253 [GO] 2021―Oct―29 Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study Anika Singanayagam, Seran Hakki, Jake Dunning, Kieran J Madon, Michael A Crone, Aleksandra Koycheva, et al. (+36)
254 [GO] 2021―Oct―29 What is the vaccine effect on reducing transmission in the context of the SARS-CoV-2 delta variant? Annelies Wilder-Smith
255 [GO] 2021―Oct―28 An insight on how to survive COVID-19 Rose Worrell
256 [GO] 2021―Oct―28 Adverse event reporting and Bell's palsy risk after COVID-19 vaccination Charles Khouri, Matthieu Roustit, Jean-Luc Cracowski
257 [GO] 2021―Oct―28 Adverse event reporting and Bell's palsy risk after COVID-19 vaccination Kwok-Chiu Chang, Fuk-Yip Kong
258 [GO] 2021―Oct―28 Adverse event reporting and Bell's palsy risk after COVID-19 vaccination - Authors' reply Ian Chi Kei Wong, Eric Yuk Fai Wan, Celine Sze Ling Chui, Xue Li, Esther Wai Yin Chan
259 [GO] 2021―Oct―28 Increasing COVID-19 vaccine uptake in Black Americans Talha Burki
260 [GO] 2021―Oct―16 Unmet need for COVID-19 therapies in community settings The Lancet Infectious Diseases
261 [GO] 2021―Oct―09 Implications of suboptimal COVID-19 vaccination coverage in Florida and Texas Pratha Sah, Seyed M Moghadas, Thomas N Vilches, Affan Shoukat, Burton H Singer, Peter J Hotez, et al. (+2)
262 [GO] 2021―Oct―05 The value of open-source clinical science in pandemic response: lessons from ISARIC
263 [GO] 2021―Sep―23 Infections, hospitalisations, and deaths averted via a nationwide vaccination campaign using the Pfizer-BioNTech BNT162b2 mRNA COVID-19 vaccine in Israel: a retrospective surveillance study Eric J Haas, John M McLaughlin, Farid Khan, Frederick J Angulo, Emilia Anis, Marc Lipsitch, et al. (+10)
264 [GO] 2021―Sep―23 Rapid COVID-19 vaccine rollout: immense success but challenges ahead Frank G Sandmann, Mark Jit
265 [GO] 2021―Sep―22 Booster shots for COVID-19-the debate continues Talha Burki
266 [GO] 2021―Sep―15 Addendum needed on COVID-19 travel study Lee Altenberg
267 [GO] 2021―Sep―15 Addendum needed on COVID-19 travel study - Authors' reply Mathew V Kiang, Elizabeth T Chin, Benjamin Q Huynh, Lloyd A C Chapman, Nathan C Lo
268 [GO] 2021―Sep―15 Safety and immunogenicity of an inactivated COVID-19 vaccine, BBIBP-CorV, in people younger than 18 years: a randomised, double-blind, controlled, phase 1/2 trial ShengLi Xia, YunTao Zhang, YanXia Wang, Hui Wang, YunKai Yang, George Fu Gao, et al. (+32)
269 [GO] 2021―Sep―14 Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial Florence Ader, Maude Bouscambert-Duchamp, Maya Hites, Nathan Peiffer-Smadja, Julien Poissy, Drifa Belhadi, et al. (+175)
270 [GO] 2021―Sep―14 India's COVID-19 vaccination drive: key challenges and resolutions Om Prakash Choudhary, Priyanka Choudhary, Indraj Singh
271 [GO] 2021―Sep―14 Prevention of host-to-host transmission by SARS-CoV-2 vaccines Darius Mostaghimi, Caroline N Valdez, Haleigh T Larson, Chaney C Kalinich, Akiko Iwasaki
272 [GO] 2021―Sep―09 Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study Denis Sauré, Miguel O'Ryan, Juan Pablo Torres, Marcela Zuniga, Emilio Santelices, Leonardo J Basso
273 [GO] 2021―Sep―09 Protection against COVID-19: beyond antibodies Marcus Vinícius Guimarães Lacerda, Daniel Youssef Bargieri
274 [GO] 2021―Sep―07 Hospitalisation among vaccine breakthrough COVID-19 infections Prerak V Juthani, Akash Gupta, Kelly A Borges, Christina C Price, Alfred I Lee, Christine H Won, Hyung J Chun
275 [GO] 2021―Sep―03 Hospitalisation associated with SARS-CoV-2 delta variant in Denmark Peter Bager, Jan Wohlfahrt, Morten Rasmussen, Mads Albertsen, Tyra Grove Krause
276 [GO] 2021―Sep―01 Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: a prospective, community-based, nested, case-control study Michela Antonelli, Rose S Penfold, Jordi Merino, Carole H Sudre, Erika Molteni, Sarah Berry, et al. (+24)
277 [GO] 2021―Aug―28 Hospital admission and emergency care attendance risk for SARS-CoV-2 delta (B.1.617.2) compared with alpha (B.1.1.7) variants of concern: a cohort study Katherine A Twohig, Tommy Nyberg, Asad Zaidi, Simon Thelwall, Mary A Sinnathamby, Shirin Aliabadi, et al. (+602)
278 [GO] 2021―Aug―28 Importance of epidemiological factors in the evaluation of transmissibility and clinical severity of SARS-CoV-2 variants Jérôme R Lechien, Sven Saussez
279 [GO] 2021―Aug―24 Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? Deepak K Tempe
280 [GO] 2021―Aug―24 Is indiscriminate use of medicines the main reason for problems faced during the second wave of COVID-19 in India? - Authors' reply Zarir Udwadia, Satchit Balsari, Abdul Ghafur
281 [GO] 2021―Aug―24 Testing indicators to monitor the COVID-19 pandemic Julien Beauté, Cornelia Adlhoch, Nick Bundle, Angeliki Melidou, Gianfranco Spiteri
282 [GO] 2021―Aug―24 An imaginary pandemic and its consequences Sanjeet Bagcchi
283 [GO] 2021―Aug―24 Memorialising Trump's pandemic (non-)response Vijay Shankar Balakrishnan
284 [GO] 2021―Aug―16 The association between COVID-19 vaccination and Bell's palsy Nicola Cirillo, Richard Doan
285 [GO] 2021―Aug―16 Persistent SARS-CoV-2 infection: the urgent need for access to treatment and trials Ed Moran, Tim Cook, Anna L Goodman, Ravindra K Gupta, Stephen Jolles, David K Menon, et al. (+5)
286 [GO] 2021―Aug―16 Bell's palsy following vaccination with mRNA (BNT162b2) and inactivated (CoronaVac) SARS-CoV-2 vaccines: a case series and nested case-control study Eric Yuk Fai Wan, Celine Sze Ling Chui, Francisco Tsz Tsun Lai, Esther Wai Yin Chan, Xue Li, Vincent Ka Chun Yan, et al. (+16)
287 [GO] 2021―Aug―13 COVID-19 vaccine equity and booster doses The Lancet Infectious Diseases
288 [GO] 2021―Aug―13 How reliable are COVID-19 burden estimates for India? You Li, Harish Nair
289 [GO] 2021―Aug―13 SARS-CoV-2 infection and mortality during the first epidemic wave in Madurai, south India: a prospective, active surveillance study Ramanan Laxminarayan, Chandra Mohan B, Vinay T G, K V Arjun Kumar, Brian Wahl, Joseph A Lewnard
290 [GO] 2021―Aug―13 Rapid genome sequencing in hospitals to identify potential vaccine-escape SARS-CoV-2 variants Luke B Snell, Penelope R Cliff, Themoula Charalampous, Adela Alcolea-Medina, Saidat A R T Ebie, Jasveen K Sehmi, et al. (+5)
291 [GO] 2021―Aug―09 Lessons about COVID-19 vaccine hesitancy among minority ethnic people in the UK Seilesh Kadambari, Samantha Vanderslott
292 [GO] 2021―Aug―04 Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? Tobias Todsen, Nikolai Kirkby, Thomas Benfield
293 [GO] 2021―Aug―04 Is oropharyngeal sampling a reliable test to detect SARS-CoV-2? - Authors' reply Nicole Ngai Yung Tsang, Hau Chi So, Dennis Kai Ming Ip
294 [GO] 2021―Aug―02 Understanding why superspreading drives the COVID-19 pandemic but not the H1N1 pandemic Paul Z Chen, Marion Koopmans, David N Fisman, Frank X Gu
295 [GO] 2021―Jul―29 Heterologous prime-boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 Matthias Tenbusch, Sofie Schumacher, Emanuel Vogel, Alina Priller, Jürgen Held, Philipp Steininger, et al. (+22)
296 [GO] 2021―Jul―28 Impact of COVID-19 on migrants and refugees Vijay Shankar Balakrishnan
297 [GO] 2021―Jul―28 Cameroon's bold response to the COVID-19 pandemic during the first and second waves Linda Esso, Emilienne Epée, Chanceline Bilounga, Aristide Abah, Achta Hamadou, Elisabeth Dibongue, et al. (+12)
298 [GO] 2021―Jul―28 Entering a labyrinth of COVID-19 stories Peter Ranscombe
299 [GO] 2021―Jul―27 Images of a world facing a pandemic Marco De Ambrogi
300 [GO] 2021―Jul―26 Safety, tolerability, and immunogenicity of an aerosolised adenovirus type-5 vector-based COVID-19 vaccine (Ad5-nCoV) in adults: preliminary report of an open-label and randomised phase 1 clinical trial Shipo Wu, Jianying Huang, Zhe Zhang, Jianyuan Wu, Jinlong Zhang, Hanning Hu, et al. (+14)
301 [GO] 2021―Jul―01 Vaccine hesitancy in the COVID-19 era Bipin Adhikari, Phaik Yeong Cheah
302 [GO] 2021―Jul―01 Old politics in pandemic management Heather MacDougal
303 [GO] 2021―Jun―28 COVID-19 vaccines for children younger than 12 years: are we ready? Xiaohui Zou, Bin Cao
304 [GO] 2021―Jun―28 The SARS-CoV-2 B.1.1.7 variant and increased clinical severity-the jury is out Benjamin Giles, Paul Meredith, Samuel Robson, Gary Smith, Anoop Chauhan
305 [GO] 2021―Jun―28 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy children and adolescents: a double-blind, randomised, controlled, phase 1/2 clinical trial Bihua Han, Yufei Song, Changgui Li, Wanqi Yang, Qingxia Ma, Zhiwei Jiang, et al. (+9)
306 [GO] 2021―Jun―23 Effectiveness of BNT162b2 and ChAdOx1 nCoV-19 COVID-19 vaccination at preventing hospitalisations in people aged at least 80 years: a test-negative, case-control study Catherine Hyams, Robin Marlow, Zandile Maseko, Jade King, Lana Ward, Kazminder Fox, et al. (+12)
307 [GO] 2021―Jun―23 Global COVID-19 vaccine inequity Talha Burki
308 [GO] 2021―Jun―23 Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study Madhumita Shrotri, Maria Krutikov, Tom Palmer, Rebecca Giddings, Borscha Azmi, Sathyavani Subbarao, et al. (+9)
309 [GO] 2021―Jun―23 Risk of hospitalisation associated with infection with SARS-CoV-2 lineage B.1.1.7 in Denmark: an observational cohort study Peter Bager, Jan Wohlfahrt, Jannik Fonager, Morten Rasmussen, Mads Albertsen, Thomas Yssing Michaelsen, et al. (+10)
310 [GO] 2021―Jun―23 Mortality and critical care unit admission associated with the SARS-CoV-2 lineage B.1.1.7 in England: an observational cohort study Martina Patone, Karen Thomas, Rob Hatch, Pui San Tan, Carol Coupland, Weiqi Liao, et al. (+6)
311 [GO] 2021―Jun―23 Single-dose SARS-CoV-2 vaccination efficacy in the elderly Maria Prendecki, Michelle Willicombe
312 [GO] 2021―Jun―23 SARS-CoV-2 variants and considerations of inferring causality on disease severity Muge Cevik, Sharmistha Mishra
313 [GO] 2021―Jun―23 The eternal cycle of pandemics Genevieve Pascal
314 [GO] 2021―Jun―21 COVID-19 and SOS tweets in India Anuraag Jena
315 [GO] 2021―Jun―10 Should we vaccinate children against SARS-CoV-2? The Lancet Infectious Diseases
316 [GO] 2021―Jun―08 Contextualising evidence-based recommendations for the second wave of the COVID-19 pandemic in India Satchit Balsari, Zarir Udwadia, Ahmed Shaikh, Abdul Ghafur, Sushila Kataria
317 [GO] 2021―Jun―07 Bell's palsy and SARS-CoV-2 vaccines-an unfolding story Nicola Cirillo, Richard Doan
318 [GO] 2021―Jun―07 Bell's palsy and SARS-CoV-2 vaccines-an unfolding story - Authors' reply Al Ozonoff, Etsuro Nanishi, Ofer Levy
319 [GO] 2021―May―28 Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong Fernando Kemta Lekpa, Sylvain Raoul Simeni Njonnou, Eric Balti, Henry Namme Luma, Simeon Pierre Choukem
320 [GO] 2021―May―28 Negative antigen RDT and RT-PCR results do not rule out COVID-19 if clinical suspicion is strong - Authors' reply Nadia Mandeng, Karl Njuwa Fai, Lisa M Bebell, Yap Boum
321 [GO] 2021―May―27 Innovations in COVID-19 testing: the road from pandemic response to control Rosanna W Peeling, David L Heymann
322 [GO] 2021―May―27 Same-day SARS-CoV-2 antigen test screening in an indoor mass-gathering live music event: a randomised controlled trial Boris Revollo, Ignacio Blanco, Pablo Soler, Jessica Toro, Nuria Izquierdo-Useros, Jordi Puig, et al. (+8)
323 [GO] 2021―May―27 Serum neutralising activity against SARS-CoV-2 variants elicited by CoronaVac Yuxin Chen, Han Shen, Rui Huang, Xin Tong, Chao Wu
324 [GO] 2021―May―26 Vaccine development lessons between HIV and COVID-19 Sandhya Vasan, Punnee Pitisuttithum
325 [GO] 2021―May―26 HIV in the age of COVID-19 Talha Burki
326 [GO] 2021―May―25 A prescription for fair housing during the COVID-19 pandemic Syed M Qasim Hussaini
327 [GO] 2021―May―19 What chikungunya teaches us about COVID-19 Fabrice Simon, Hugh Watson, Jean-Baptiste Meynard, Vincent Pommier de Santi, Jean-Nicolas Tournier
328 [GO] 2021―May―19 SARS-CoV-2 B.1.1.7 and B.1.351 spike variants bind human ACE2 with increased affinity Muthukumar Ramanathan, Ian D Ferguson, Weili Miao, Paul A Khavari
329 [GO] 2021―May―18 Ongoing and future COVID-19 vaccine clinical trials: challenges and opportunities Rafael Dal-Ré, Linda-Gail Bekker, Christian Gluud, Søren Holm, Vivekanand Jha, Gregory A Poland, et al. (+6)
330 [GO] 2021―May―14 The rocky road to universal COVID-19 vaccination The Lancet Infectious Diseases
331 [GO] 2021―May―11 Applying prospective genomic surveillance to support investigation of hospital-onset COVID-19 William L Hamilton, Tom Fieldman, Aminu Jahun, Ben Warne, Christopher J R Illingworth, Chris Jackson, et al. (+37)
332 [GO] 2021―May―11 Post-acute conditions of patients with COVID-19 not requiring hospital admission Lixue Huang, Bin Cao
333 [GO] 2021―May―11 Post-acute effects of SARS-CoV-2 infection in individuals not requiring hospital admission: a Danish population-based cohort study Lars Christian Lund, Jesper Hallas, Henrik Nielsen, Anders Koch, Stine Hasling Mogensen, Nikolai Constantin Brun, et al. (+3)
334 [GO] 2021―May―04 SARS-CoV-2 rapid antigen detection tests Sotirios Fouzas
335 [GO] 2021―May―04 SARS-CoV-2 rapid antigen detection tests Thomas Weitzel, Caricia Pérez, Danixa Tapia, Paulette Legarraga, Lorena Porte
336 [GO] 2021―May―04 SARS-CoV-2 rapid antigen detection tests - Authors' reply Rosanna W Peeling, Piero Olliaro, Debrah Boeras, Noah Fongwen
337 [GO] 2021―Apr―27 Symptom study app provides real-world data on COVID-19 vaccines Ruth E Drury, Daniel O'Connor
338 [GO] 2021―Apr―27 Vaccine side-effects and SARS-CoV-2 infection after vaccination in users of the COVID Symptom Study app in the UK: a prospective observational study Cristina Menni, Kerstin Klaser, Anna May, Lorenzo Polidori, Joan Capdevila, Panayiotis Louca, et al. (+22)
339 [GO] 2021―Apr―23 Bilateral infiltrates in a health-care worker during the COVID-19 pandemic Otmar Schindler, Gerald Steiner, Elisabeth Trattner, Eva Schmon, Wolfgang Kuebler, Eveline Kink
340 [GO] 2021―Apr―23 CEPI prepares for future pandemics and epidemics Udani Samarasekera
341 [GO] 2021―Apr―20 COVID-19 herd immunity by immunisation: are children in the herd? Stephen Obaro
342 [GO] 2021―Apr―20 Recombinant protein vaccines against SARS-CoV-2 Sarah C Gilbert, Teresa Lambe
343 [GO] 2021―Apr―20 Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1-2, dose-ranging study Paul A Goepfert, Bo Fu, Anne-Laure Chabanon, Matthew I Bonaparte, Matthew G Davis, Brandon J Essink, et al. (+16)
344 [GO] 2021―Apr―20 Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial Keith J Chappell, Francesca L Mordant, Zheyi Li, Danushka K Wijesundara, Paula Ellenberg, Julia A Lackenby, et al. (+29)
345 [GO] 2021―Apr―15 SARS-CoV-2 incidence and vaccine escape Robin N Thompson, Edward M Hill, Julia R Gog
346 [GO] 2021―Apr―15 Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases Mattia Trunfio, Andrea Calcagno, Stefano Bonora, Giovanni Di Perri
347 [GO] 2021―Apr―15 Lowering SARS-CoV-2 viral load might affect transmission but not disease severity in secondary cases - Authors' reply Matthew A Spinelli, George Rutherford, Monica Gandhi
348 [GO] 2021―Apr―14 Beyond COVID-19-will self-sampling and testing become the norm? Yap Boum, Sara Eyangoh, Marie-Claire Okomo
349 [GO] 2021―Apr―14 Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study Dan Frampton, Tommy Rampling, Aidan Cross, Heather Bailey, Judith Heaney, Matthew Byott, et al. (+23)
350 [GO] 2021―Apr―14 Diagnostic performance of different sampling approaches for SARS-CoV-2 RT-PCR testing: a systematic review and meta-analysis Nicole Ngai Yung Tsang, Hau Chi So, Ka Yan Ng, Benjamin J Cowling, Gabriel M Leung, Dennis Kai Ming Ip
351 [GO] 2021―Apr―14 Lack of detail in population-level data impedes analysis of SARS-CoV-2 variants of concern and clinical outcomes Sean Wei Xiang Ong, Barnaby Edward Young, David Chien Lye
352 [GO] 2021―Apr―09 “In an ocean of ashes, islands of order”: WHO's SARS-CoV-2 origin report The Lancet Infectious Diseases
353 [GO] 2021―Apr―01 The interplay between COVID-19 restrictions and vaccination Chad R Wells, Alison P Galvani
354 [GO] 2021―Apr―01 Prioritising COVID-19 vaccination in changing social and epidemiological landscapes: a mathematical modelling study Peter C Jentsch, Madhur Anand, Chris T Bauch
355 [GO] 2021―Mar―25 Rolling out COVID-19 antigen rapid diagnostic tests: the time is now Rosanna W Peeling, Piero Olliaro
356 [GO] 2021―Mar―25 The effect of seasonal respiratory virus transmission on syndromic surveillance for COVID-19 in Ontario, Canada Arjuna S Maharaj, Jennifer Parker, Jessica P Hopkins, Effie Gournis, Isaac I Bogoch, Benjamin Rader, et al. (+8)
357 [GO] 2021―Mar―25 Performance and operational feasibility of antigen and antibody rapid diagnostic tests for COVID-19 in symptomatic and asymptomatic patients in Cameroon: a clinical, prospective, diagnostic accuracy study Yap Boum, Karl Njuwa Fai, Birgit Nicolay, Akenji Blaise Mboringong, Lisa M Bebell, Mark Ndifon, et al. (+23)
358 [GO] 2021―Mar―24 Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials Shilong Yang, Yan Li, Lianpan Dai, Jianfeng Wang, Peng He, Changgui Li, et al. (+23)
359 [GO] 2021―Mar―24 Ebola and COVID-19 in DR Congo and Guinea Paul Adepoju
360 [GO] 2021―Mar―24 COVID-19 vaccination in Ukraine Edward Holt
361 [GO] 2021―Mar―24 Is there space for a three-dose vaccine to fight the spread of SARS-CoV-2? Patrick L Iversen, Sina Bavari
362 [GO] 2021―Mar―24 Behind Cuba's successful pandemic response Talha Burki
363 [GO] 2021―Mar―23 Routine asymptomatic testing strategies for airline travel during the COVID-19 pandemic: a simulation study Mathew V Kiang, Elizabeth T Chin, Benjamin Q Huynh, Lloyd A C Chapman, Isabel Rodríguez-Barraquer, Bryan Greenhouse, et al. (+5)
364 [GO] 2021―Mar―20 Navigating post-vaccine COVID-19 futures in the health and economic context C Raina MacIntyre
365 [GO] 2021―Mar―20 Risking further COVID-19 waves despite vaccination Sebastian Contreras, Viola Priesemann
366 [GO] 2021―Mar―20 Vaccination and non-pharmaceutical interventions for COVID-19: a mathematical modelling study Sam Moore, Edward M Hill, Michael J Tildesley, Louise Dyson, Matt J Keeling
367 [GO] 2021―Mar―20 The potential health and economic value of SARS-CoV-2 vaccination alongside physical distancing in the UK: a transmission model-based future scenario analysis and economic evaluation Frank G Sandmann, Nicholas G Davies, Anna Vassall, W John Edmunds, Mark Jit, Fiona Yueqian Sun, et al. (+45)
368 [GO] 2021―Mar―20 Nurses at the frontline of public health emergency preparedness and response: lessons learned from the HIV/AIDS pandemic and emerging infectious disease outbreaks Vincent Guilamo-Ramos, Marco Thimm-Kaiser, Adam Benzekri, Andrew Hidalgo, Yzette Lanier, Sheila Tlou, et al. (+3)
369 [GO] 2021―Mar―11 Alternatives to conventional hospitalisation that enhance health systems' capacity to treat COVID-19 David Nicolás, Emmanuel Coloma, Juan M Pericàs
370 [GO] 2021―Mar―09 Border screening is an essential component of COVID-19 testing strategies in Vanuatu Caroline van Gemert, Posikai Samuel Tapo, Kalkie Sero, Len Tarivonda, Philippe Guyant, Tessa B. Knox, et al. (+10)
371 [GO] 2021―Mar―09 Adjuvantation helps to optimise COVID-19 vaccine candidate Jing-Xin Li, Feng-Cai Zhu
372 [GO] 2021―Mar―09 Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy Puja Mehta, Christopher B Bunker, Coziana Ciurtin, Joanna C Porter, Rachel C Chambers, Charalampia Papdopoulou, et al. (+6)
373 [GO] 2021―Mar―09 Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial Raches Ella, Siddharth Reddy, Harsh Jogdand, Vamshi Sarangi, Brunda Ganneru, Sai Prasad, et al. (+20)
374 [GO] 2021―Mar―01 Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis Kauser Jabeen, Joveria Farooqi, Muhammad Irfan, Syed Ahsan Ali, David W Denning
375 [GO] 2021―Mar―01 Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis Nitipong Permpalung, Johan Maertens, Kieren A Marr
376 [GO] 2021―Mar―01 Diagnostic dilemma in COVID-19-associated pulmonary aspergillosis - Authors' reply Philipp Koehler, P Lewis White, Paul E Verweij, Oliver A Cornely
377 [GO] 2021―Mar―01 Pandemic psyche Vijay Shankar Balakrishnan
378 [GO] 2021―Feb―24 Anticipating outcomes for patients with COVID-19 and identifying prognosis patterns Michael Darmon, Guillaume Dumas
379 [GO] 2021―Feb―24 Scaling up COVID-19 rapid antigen tests: promises and challenges Rosanna W Peeling, Piero L Olliaro, Debrah I Boeras, Noah Fongwen
380 [GO] 2021―Feb―24 Identification and validation of clinical phenotypes with prognostic implications in patients admitted to hospital with COVID-19: a multicentre cohort study Belén Gutiérrez-Gutiérrez, María Dolores del Toro, Alberto M Borobia, Antonio Carcas, Inmaculada Jarrín, María Yllescas, et al. (+935)
381 [GO] 2021―Feb―24 Bell's palsy and SARS-CoV-2 vaccines Al Ozonoff, Etsuro Nanishi, Ofer Levy
382 [GO] 2021―Feb―24 COVID-19 among American Indians and Alaska Natives Talha Burki
383 [GO] 2021―Feb―24 The world's largest COVID-19 vaccination campaign Sanjeet Bagcchi
384 [GO] 2021―Feb―24 Feelings towards COVID-19 vaccination in Africa Udani Samarasekera
385 [GO] 2021―Feb―23 Importance of non-pharmaceutical interventions in lowering the viral inoculum to reduce susceptibility to infection by SARS-CoV-2 and potentially disease severity Matthew A Spinelli, David V Glidden, Efstathios D Gennatas, Michel Bielecki, Chris Beyrer, George Rutherford, et al. (+3)
386 [GO] 2021―Feb―18 What does 95% COVID-19 vaccine efficacy really mean? Piero Olliaro
387 [GO] 2021―Feb―11 The COVID-19 exit strategy-why we need to aim low The Lancet Infectious Diseases
388 [GO] 2021―Feb―09 CovMT: an interactive SARS-CoV-2 mutation tracker, with a focus on critical variants Intikhab Alam, Aleksandar Radovanovic, Roberto Incitti, Allan A Kamau, Mohammed Alarawi, Esam I Azhar, Takashi Gojobori
389 [GO] 2021―Feb―05 Transmission of COVID-19 in 282 clusters in Catalonia, Spain: a cohort study Michael Marks, Pere Millat-Martinez, Dan Ouchi, Chrissy h Roberts, Andrea Alemany, Marc Corbacho-Monné, et al. (+12)
390 [GO] 2021―Feb―05 In favour of a bespoke COVID-19 vaccines compensation scheme Duncan Fairgrieve, Søren Holm, Geraint Howells, Claas Kirchhelle, Samantha Vanderslott
391 [GO] 2021―Feb―05 Inactivated COVID-19 vaccines to make a global impact Patrick L Iversen, Sina Bavari
392 [GO] 2021―Feb―05 Understanding the drivers of transmission of SARS-CoV-2 Laura Cornelissen, Emmanuel André
393 [GO] 2021―Feb―05 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Zhiwei Wu, Yaling Hu, Miao Xu, Zhen Chen, Wanqi Yang, Zhiwei Jiang, et al. (+9)
394 [GO] 2021―Feb―03 Seroprevalence of anti-SARS-CoV-2 antibodies after the second pandemic peak Silvia Stringhini, María-Eugenia Zaballa, Javier Perez-Saez, Nick Pullen, Carlos de Mestral, Attilio Picazio, et al. (+16)
395 [GO] 2021―Jan―29 Neighbours in time of COVID-19 Rebecca Barksby
396 [GO] 2021―Jan―25 Regulatory approval of COVID-19 vaccine for restricted use in clinical trial mode Prasanta Raghab Mohapatra, Baijayantimala Mishra
397 [GO] 2021―Jan―22 Optimism and caution for an inactivated COVID-19 vaccine Christina A Rostad, Evan J Anderson
398 [GO] 2021―Jan―22 Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: a double-blind, randomised, phase 1 trial Raches Ella, Krishna Mohan Vadrevu, Harsh Jogdand, Sai Prasad, Siddharth Reddy, Vamshi Sarangi, et al. (+18)
399 [GO] 2021―Jan―20 Structured serological testing is an essential component to investigating SARS-CoV-2 reinfection Scott J C Pallett, Rachael Jones, Paul Randell, Gary W Davies, Luke S P Moore
400 [GO] 2021―Jan―19 Household transmission of SARS-CoV-2 and risk factors for susceptibility and infectivity in Wuhan: a retrospective observational study Fang Li, Yuan-Yuan Li, Ming-Jin Liu, Li-Qun Fang, Natalie E Dean, Gary W K Wong, et al. (+13)
401 [GO] 2021―Jan―19 COVID-19 through the Latinx infectious disease doctor's eyes Annelys Roque Gardner
402 [GO] 2021―Jan―18 Keeping childhood immunisation rates stable during the COVID-19 pandemic Anna A Jarchow-MacDonald, Ruth Burns, Jessica Miller, Linda Kerr, Lorna J Willocks
403 [GO] 2021―Jan―18 Long COVID in the skin: a registry analysis of COVID-19 dermatological duration Devon E McMahon, Antonia E Gallman, George J Hruza, Misha Rosenbach, Jules B Lipoff, Seemal R Desai, et al. (+6)
404 [GO] 2021―Jan―14 First detection of SARS-CoV-2 spike protein N501 mutation in Italy in August, 2020 Simona Fiorentini, Serena Messali, Alberto Zani, Francesca Caccuri, Marta Giovanetti, Massimo Ciccozzi, Arnaldo Caruso
405 [GO] 2021―Jan―09 Multiple testing and the effect of NPIs on the spread of SARS-CoV-2 Christoph Rothe
406 [GO] 2020―Dec―24 Tuberculosis and malaria in the age of COVID-19 The Lancet Infectious Diseases
407 [GO] 2020―Dec―24 Association of tiered restrictions and a second lockdown with COVID-19 deaths and hospital admissions in England: a modelling study Nicholas G Davies, Rosanna C Barnard, Christopher I Jarvis, Timothy W Russell, Malcolm G Semple, Mark Jit, W John Edmunds
408 [GO] 2020―Dec―24 A decentralised point-of-care testing model to address inequities in the COVID-19 response Belinda Hengel, Louise Causer, Susan Matthews, Kirsty Smith, Kelly Andrewartha, Steven Badman, et al. (+10)
409 [GO] 2020―Dec―24 COVID-19 testing in Slovakia Edward Holt
410 [GO] 2020―Dec―24 Equitable distribution of COVID-19 vaccines Talha Burki
411 [GO] 2020―Dec―18 Persistence of IgG response to SARS-CoV-2 Els Duysburgh, Laure Mortgat, Cyril Barbezange, Katelijne Dierick, Natalie Fischer, Leo Heyndrickx, et al. (+6)
412 [GO] 2020―Dec―17 Concerns and motivations about COVID-19 vaccination Rachael H Dodd, Kristen Pickles, Brooke Nickel, Erin Cvejic, Julie Ayre, Carys Batcup, et al. (+6)
413 [GO] 2020―Dec―17 SARS-CoV-2 antibody seroprevalence in the general population and high-risk occupational groups across 18 cities in Iran: a population-based cross-sectional study Hossein Poustchi, Maryam Darvishian, Zahra Mohammadi, Amaneh Shayanrad, Alireza Delavari, Ayad Bahadorimonfared, et al. (+36)
414 [GO] 2020―Dec―16 An interactive tracker for ceasefires in the time of COVID-19 John Allison, Sanja Badanjak, Benjamin Bach, Christine Bell, Devanjan Bhattacharya, Fiona Knaussel, Laura Wise
415 [GO] 2020―Dec―16 Defining and managing COVID-19-associated pulmonary aspergillosis: the 2020 ECMM/ISHAM consensus criteria for research and clinical guidance Philipp Koehler, Matteo Bassetti, Arunaloke Chakrabarti, Sharon C A Chen, Arnaldo Lopes Colombo, Martin Hoenigl, et al. (+16)
416 [GO] 2020―Dec―13 The words that shaped COVID-19 Amesh Adalja
417 [GO] 2020―Dec―09 The granting of emergency use designation to COVID-19 candidate vaccines: implications for COVID-19 vaccine trials Jerome Amir Singh, Ross E G Upshur
418 [GO] 2020―Dec―09 SARS-CoV-2 infection and transmission in educational settings: a prospective, cross-sectional analysis of infection clusters and outbreaks in England Sharif A Ismail, Vanessa Saliba, Jamie Lopez Bernal, Mary E Ramsay, Shamez N Ladhani
419 [GO] 2020―Dec―09 The role of schools and school-aged children in SARS-CoV-2 transmission Stefan Flasche, W John Edmunds
420 [GO] 2020―Dec―07 Fungal infections should be part of the core outcome set for COVID-19 Paul E Verweij, Alexandre Alanio
421 [GO] 2020―Dec―07 Fungal infections should be part of the core outcome set for COVID-19 - Authors' reply John C Marshall, Srinivas Murthy, Janet Diaz
422 [GO] 2020―Dec―07 A public health ethic should inform policies on COVID-19 immunity passports Françoise Baylis, Natalie Kofler
423 [GO] 2020―Dec―07 A public health ethic should inform policies on COVID-19 immunity passports - Authors' reply Rebecca C H Brown, Julian Savulescu, Dominic Kelly, Dominic Wilkinson
424 [GO] 2020―Dec―07 Towards an accurate and systematic characterisation of persistently asymptomatic infection with SARS-CoV-2 Eric A Meyerowitz, Aaron Richterman, Isaac I Bogoch, Nicola Low, Muge Cevik
425 [GO] 2020―Dec―01 Antibiotic prescribing in general practice during COVID-19 Richard Armitage, Laura B Nellums
426 [GO] 2020―Nov―26 The place for remdesivir in COVID-19 treatment Barnaby Young, Thuan Tong Tan, Yee Sin Leo
427 [GO] 2020―Nov―24 A case of SARS-CoV-2 reinfection in Ecuador Belén Prado-Vivar, Mónica Becerra-Wong, Juan José Guadalupe, Sully Márquez, Bernardo Gutierrez, Patricio Rojas-Silva, et al. (+4)
428 [GO] 2020―Nov―21 SARS-CoV-2 and the human-animal interface: outbreaks on mink farms Marion Koopmans
429 [GO] 2020―Nov―20 Kinetics and seroprevalence of SARS-CoV-2 antibodies in children Cathal Roarty, Claire Tonry, Lisa McFetridge, Hannah Mitchell, Chris Watson, Thomas Waterfield, et al. (+23)
430 [GO] 2020―Nov―20 Ct values and infectivity of SARS-CoV-2 on surfaces Günter Kampf, Sebastian Lemmen, Miranda Suchomel
431 [GO] 2020―Nov―19 Expecting the unexpected with COVID-19 vaccines Naor Bar-Zeev, Sonali Kochhar
432 [GO] 2020―Nov―19 Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial Yanjun Zhang, Gang Zeng, Hongxing Pan, Changgui Li, Yaling Hu, Kai Chu, et al. (+14)
433 [GO] 2020―Nov―13 Hydroxychloroquine and COVID-19: a tale of populism and obscurantism Nathan Peiffer-Smadja, Mathieu E Rebeaud, Anthony Guihur, Yahya Mahamat-Saleh, Thibault Fiolet
434 [GO] 2020―Nov―03 Limitations of using mobile phone data to model COVID-19 transmission in the USA Hamada S Badr, Lauren M Gardner
435 [GO] 2020―Nov―03 SARS-CoV-2 seroprevalence and transmission risk factors among high-risk close contacts: a retrospective cohort study Oon Tek Ng, Kalisvar Marimuthu, Vanessa Koh, Junxiong Pang, Kyaw Zaw Linn, Jie Sun, et al. (+19)
436 [GO] 2020―Oct―27 What defines an efficacious COVID-19 vaccine? A review of the challenges assessing the clinical efficacy of vaccines against SARS-CoV-2 Susanne H Hodgson, Kushal Mansatta, Garry Mallett, Victoria Harris, Katherine R W Emary, Andrew J Pollard
437 [GO] 2020―Oct―23 Estimating the COVID-19 R number: a bargain with the devil? Chris T Bauch
438 [GO] 2020―Oct―23 The temporal association of introducing and lifting non-pharmaceutical interventions with the time-varying reproduction number (R) of SARS-CoV-2: a modelling study across 131 countries You Li, Harry Campbell, Durga Kulkarni, Alice Harpur, Madhurima Nundy, Xin Wang, Harish Nair
439 [GO] 2020―Oct―19 Estimating the infection-fatality risk of SARS-CoV-2 in New York City during the spring 2020 pandemic wave: a model-based analysis Wan Yang, Sasikiran Kandula, Mary Huynh, Sharon K Greene, Gretchen Van Wye, Wenhui Li, et al. (+6)
440 [GO] 2020―Oct―15 A promising inactivated whole-virion SARS-CoV-2 vaccine Irina Isakova-Sivak, Larisa Rudenko
441 [GO] 2020―Oct―15 Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBIBP-CorV: a randomised, double-blind, placebo-controlled, phase 1/2 trial Shengli Xia, Yuntao Zhang, Yanxia Wang, Hui Wang, Yunkai Yang, George Fu Gao, et al. (+26)
442 [GO] 2020―Oct―12 What reinfections mean for COVID-19 Akiko Iwasaki
443 [GO] 2020―Oct―12 Genomic evidence for reinfection with SARS-CoV-2: a case study Richard L Tillett, Joel R Sevinsky, Paul D Hartley, Heather Kerwin, Natalie Crawford, Andrew Gorzalski, et al. (+7)
444 [GO] 2020―Oct―09 Beyond COVID-19-a paradigm shift in infection management? Maria J G T Vehreschild, Evelina Tacconelli, Christian G Giske, Andreas Peschel
445 [GO] 2020―Oct―08 China's successful control of COVID-19 Talha Burki
446 [GO] 2020―Oct―08 The intersection of COVID-19 and mental health The Lancet Infectious Diseases
447 [GO] 2020―Oct―06 MERS-CoV in Africa-an enigma with relevance to COVID-19 Stanley Perlman, Alimuddin Zumla
448 [GO] 2020―Oct―06 T-cell responses to MERS coronavirus infection in people with occupational exposure to dromedary camels in Nigeria: an observational cohort study Chris Ka Pun Mok, Airu Zhu, Jingxian Zhao, Eric H Y Lau, Junxiang Wang, Zhao Chen, et al. (+12)
449 [GO] 2020―Oct―06 The role of louse-transmitted diseases in historical plague pandemics Rémi Barbieri, Michel Drancourt, Didier Raoult
450 [GO] 2020―Oct―05 Change in obstetric attendance and activities during the COVID-19 pandemic Asma Khalil, Peter von Dadelszen, Erkan Kalafat, Mercede Sebghati, Shamez Ladhani, Austin Ugwumadu, et al. (+3)
451 [GO] 2020―Oct―05 COVID-19: the deadly threat of misinformation Jane Galvão
452 [GO] 2020―Sep―29 Decarceration and community re-entry in the COVID-19 era Carlos Franco-Paredes, Nazgol Ghandnoosh, Hassan Latif, Martin Krsak, Andres F Henao-Martinez, Megan Robins, et al. (+2)
453 [GO] 2020―Sep―29 Low risk of SARS-CoV-2 transmission by fomites in real-life conditions Mario U Mondelli, Marta Colaneri, Elena M Seminari, Fausto Baldanti, Raffaele Bruno
454 [GO] 2020―Sep―24 COVID-19 claims another victim Talha Burki
455 [GO] 2020―Sep―24 COVID-19 in Africa: half a year later Munyaradzi Makoni
456 [GO] 2020―Sep―24 The complexities of SARS-CoV-2 serology Catherine F Houlihan, Rupert Beale
457 [GO] 2020―Sep―24 Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison Mark Ainsworth, Monique Andersson, Kathryn Auckland, J Kenneth Baillie, Eleanor Barnes, Sally Beer, et al. (+124)
458 [GO] 2020―Sep―21 COVID-19 in malaria-endemic regions: potential consequences for malaria intervention coverage, morbidity, and mortality Miranda I Teboh-Ewungkem, Gideon A Ngwa
459 [GO] 2020―Sep―21 Indirect effects of the COVID-19 pandemic on malaria intervention coverage, morbidity, and mortality in Africa: a geospatial modelling analysis Daniel J Weiss, Amelia Bertozzi-Villa, Susan F Rumisha, Punam Amratia, Rohan Arambepola, Katherine E Battle, et al. (+15)
460 [GO] 2020―Sep―15 Associations between phone mobility data and COVID-19 cases Oliver Gatalo, Katie Tseng, Alisa Hamilton, Gary Lin, Eili Klein
461 [GO] 2020―Sep―14 Intention to vaccinate against COVID-19 in Australia Anthea Rhodes, Monsurul Hoq, Mary-Anne Measey, Margie Danchin
462 [GO] 2020―Sep―11 SARS-CoV-2 transmission via speech-generated respiratory droplets Adriaan Bax, Christina E Bax, Valentyn Stadnytskyi, Philip Anfinrud
463 [GO] 2020―Sep―10 Curing COVID-19 The Lancet Infectious Diseases
464 [GO] 2020―Sep―01 Long-term consequences of COVID-19: research needs Dana Yelin, Eytan Wirtheim, Pauline Vetter, Andre C Kalil, Judith Bruchfeld, Michael Runold, et al. (+9)
465 [GO] 2020―Aug―26 Air travel in the time of COVID-19 The Lancet Infectious Diseases
466 [GO] 2020―Aug―26 The origin of SARS-CoV-2 Talha Burki
467 [GO] 2020―Aug―18 Comparison of molecular testing strategies for COVID-19 control: a mathematical modelling study Nicholas C Grassly, Margarita Pons-Salort, Edward P K Parker, Peter J White, Neil M Ferguson, Kylie Ainslie, et al. (+37)
468 [GO] 2020―Aug―17 COVID-19 and multisystem inflammatory syndrome in children and adolescents Li Jiang, Kun Tang, Mike Levin, Omar Irfan, Shaun K Morris, Karen Wilson, et al. (+2)
469 [GO] 2020―Aug―11 Evolving ethics of COVID-19 challenge trials David Manheim
470 [GO] 2020―Aug―11 COVID-19 pandemic more than a century after the Spanish flu Emilie Javelle, Didier Raoult
471 [GO] 2020―Aug―11 Inclusion of pregnant women in COVID-19 vaccine development Paul T Heath, Kirsty Le Doare, Asma Khalil
472 [GO] 2020―Aug―11 Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics Fabian Standl, Karl-Heinz Jöckel, Bastian Brune, Börge Schmidt, Andreas Stang
473 [GO] 2020―Aug―10 A need for open public data standards and sharing in light of COVID-19 Lauren Gardner, Jeremy Ratcliff, Ensheng Dong, Aaron Katz
474 [GO] 2020―Aug―10 Dental procedure aerosols and COVID-19 Joel B Epstein, Kenneth Chow, Richard Mathias
475 [GO] 2020―Aug―07 SARS-CoV-2 epidemic in African countries-are we losing perspective? Andreas Kalk, Andreas Schultz
476 [GO] 2020―Aug―06 Elimination of COVID-19: what would it look like and is it possible? Anita E Heywood, C Raina Macintyre
477 [GO] 2020―Aug―04 Excess mortality from COVID-19 in an English sentinel network population Mark Joy, F D Richard Hobbs, Dylan McGagh, Oluwafunmi Akinyemi, Simon de Lusignan
478 [GO] 2020―Aug―04 SeroTracker: a global SARS-CoV-2 seroprevalence dashboard Rahul K Arora, Abel Joseph, Jordan Van Wyk, Simona Rocco, Austin Atmaja, Ewan May, et al. (+6)
479 [GO] 2020―Aug―03 Risk of COVID-19 in health-care workers in Denmark: an observational cohort study Kasper Iversen, Henning Bundgaard, Rasmus B Hasselbalch, Jonas H Kristensen, Pernille B Nielsen, Mia Pries-Heje, et al. (+22)
480 [GO] 2020―Aug―03 Using serological data to understand unobserved SARS-CoV-2 risk in health-care settings Adam J Kucharski, Eric J Nilles
481 [GO] 2020―Jul―29 New WHO road map for NTD recovery post COVID-19 Tim Jesudason
482 [GO] 2020―Jul―29 Observations of the global epidemiology of COVID-19 from the prepandemic period using web-based surveillance: a cross-sectional analysis Fatimah S Dawood, Philip Ricks, Gibril J Njie, Michael Daugherty, William Davis, James A Fuller, et al. (+13)
483 [GO] 2020―Jul―29 The indirect impact of COVID-19 on women Talha Burki
484 [GO] 2020―Jul―28 Lung fibrosis: an undervalued finding in COVID-19 pathological series Federica Grillo, Emanuela Barisione, Lorenzo Ball, Luca Mastracci, Roberto Fiocca
485 [GO] 2020―Jul―24 Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential Rosanna W Peeling, Debrah Boeras, Annelies Wilder-Smith, Amadou Sall, John Nkengasong
486 [GO] 2020―Jul―23 Monitoring approaches for health-care workers during the COVID-19 pandemic Julia A Bielicki, Xavier Duval, Nina Gobat, Herman Goossens, Marion Koopmans, Evelina Tacconelli, Sylvie van der Werf
487 [GO] 2020―Jul―21 Communicating with children about COVID-19 Fiona Mitchell
488 [GO] 2020―Jul―17 Potential factors linked to high COVID-19 death rates in British minority ethnic groups Marion Cook
489 [GO] 2020―Jul―17 The COVID-19 infodemic The Lancet Infectious Diseases
490 [GO] 2020―Jul―17 Serology testing in the COVID-19 pandemic response Rosanna W Peeling, Catherine J Wedderburn, Patricia J Garcia, Debrah Boeras, Noah Fongwen, John Nkengasong, et al. (+3)
491 [GO] 2020―Jul―14 Rapid implementation of SARS-CoV-2 sequencing to investigate cases of health-care associated COVID-19: a prospective genomic surveillance study Luke W Meredith, William L Hamilton, Ben Warne, Charlotte J Houldcroft, Myra Hosmillo, Aminu S Jahun, et al. (+22)
492 [GO] 2020―Jul―14 COVID-19: from rapid genome sequencing to fast decisions Ole Behrmann, Martin Spiegel
493 [GO] 2020―Jul―14 Serology-informed estimates of SARS-CoV-2 infection fatality risk in Geneva, Switzerland Javier Perez-Saez, Stephen A Lauer, Laurent Kaiser, Simon Regard, Elisabeth Delaporte, Idris Guessous, et al. (+96)
494 [GO] 2020―Jul―14 Challenges and issues of SARS-CoV-2 pool testing Jens N Eberhardt, Nikolas P Breuckmann, Christiane S Eberhardt
495 [GO] 2020―Jul―14 Challenges and issues of SARS-CoV-2 pool testing Baijayantimala Mishra, Bijayini Behera, Monalisa Mohanty, Akshatha Ravindra, Jai Ranjan
496 [GO] 2020―Jul―14 Challenges and issues of SARS-CoV-2 pool testing Jaehyeon Lee, So Yeon Kim, Heungsup Sung, Sang Won Lee, Hyukmin Lee, Kyoung Ho Roh, et al. (+2)
497 [GO] 2020―Jul―14 Challenges and issues of SARS-CoV-2 pool testing - Authors' reply Stefan Lohse, Thorsten Pfuhl, Barbara Berkó-Göttel, Barbara Gärtner, Sören L Becker, Sophie Schneitler, Sigrun Smola
498 [GO] 2020―Jul―06 Assessment of patients who tested positive for COVID-19 after recovery Qi Mei, Jun Li, Ronghui Du, Xianglin Yuan, Ming Li, Jian Li
499 [GO] 2020―Jul―03 Exaggerated risk of transmission of COVID-19 by fomites Emanuel Goldman
500 [GO] 2020―Jul―03 Comparing SARS-CoV-2 with SARS-CoV and influenza pandemics Eskild Petersen, Marion Koopmans, Unyeong Go, Davidson H Hamer, Nicola Petrosillo, Francesco Castelli, et al. (+3)
501 [GO] 2020―Jul―03 Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities Ana Hoxha, Chloe Wyndham-Thomas, Sofieke Klamer, Dominique Dubourg, Melissa Vermeulen, Naima Hammami, Laura Cornelissen
502 [GO] 2020―Jul―02 COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study Reina S Sikkema, Suzan D Pas, David F Nieuwenhuijse, Áine O'Toole, Jaco Verweij, Anne van der Linden, et al. (+22)
503 [GO] 2020―Jul―01 Association between mobility patterns and COVID-19 transmission in the USA: a mathematical modelling study Hamada S Badr, Hongru Du, Maximilian Marshall, Ensheng Dong, Marietta M Squire, Lauren M Gardner
504 [GO] 2020―Jun―30 Willingness to vaccinate against COVID-19 in Australia Rachael H Dodd, Erin Cvejic, Carissa Bonner, Kristen Pickles, Kirsten J McCaffery, Julie Ayre, et al. (+6)
505 [GO] 2020―Jun―30 Surfing the COVID-19 scientific wave Mohamed Abbas, Didier Pittet
506 [GO] 2020―Jun―24 COVID-19 in Iran: round 2 Priya Venkatesan
507 [GO] 2020―Jun―24 Stigma during the COVID-19 pandemic Sanjeet Bagcchi
508 [GO] 2020―Jun―24 High COVID-19 testing rate in Portugal Marcia Triunfol
509 [GO] 2020―Jun―24 COVID-19: Playing away the pandemic Vijay Shankar Balakrishnan
510 [GO] 2020―Jun―24 Acute respiratory distress syndrome during a pandemic-an obvious diagnosis? Alexander C Reisinger, Gernot Schilcher, Juergen Prattes, Ines Zollner-Schwetz, Philipp Eller
511 [GO] 2020―Jun―19 Association of mediastinal lymphadenopathy with COVID-19 prognosis Francesco Sardanelli, Andrea Cozzi, Lorenzo Monfardini, Claudio Bnà, Riccardo Alessandro Foà, Angelo Spinazzola, et al. (+4)
512 [GO] 2020―Jun―18 Negative SARS-CoV-2 PCR in patients with chilblain-like lesions Thomas Hubiche, Florence Le Duff, Christine Chiaverini, Valérie Giordanengo, Thierry Passeron
513 [GO] 2020―Jun―17 Household secondary attack rate of COVID-19 and associated determinants in Guangzhou, China: a retrospective cohort study Qin-Long Jing, Ming-Jin Liu, Zhou-Bin Zhang, Li-Qun Fang, Jun Yuan, An-Ran Zhang, et al. (+10)
514 [GO] 2020―Jun―17 Household studies provide key insights on the transmission of, and susceptibility to, SARS-CoV-2 Virginia E Pitzer, Ted Cohen
515 [GO] 2020―Jun―16 Case isolation, contact tracing, and physical distancing are pillars of COVID-19 pandemic control, not optional choices Chandini Raina MacIntyre
516 [GO] 2020―Jun―16 Hydroxychloroquine use in COVID-19: what is the basis for baseline tests? TP Afra, Muhammed Razmi T, Anuradha Bishnoi, NA Bishurul Hafi
517 [GO] 2020―Jun―16 Effectiveness of isolation, testing, contact tracing, and physical distancing on reducing transmission of SARS-CoV-2 in different settings: a mathematical modelling study Adam J Kucharski, Petra Klepac, Andrew J K Conlan, Stephen M Kissler, Maria L Tang, Hannah Fry, et al. (+45)
518 [GO] 2020―Jun―15 Appropriate selection of convalescent plasma donors for COVID-19 Richard S Tedder, Malcolm G Semple
519 [GO] 2020―Jun―15 COVID-19 in Africa: between hope and reality Francine Ntoumi, Thirumalaisamy P Velavan
520 [GO] 2020―Jun―15 Seroconversion in household members of COVID-19 outpatients Rebecca J Cox, Karl A Brokstad, Florian Krammer, Nina Langeland, Bjørn Blomberg, Kanika Kuwelker, et al. (+11)
521 [GO] 2020―Jun―12 A minimal common outcome measure set for COVID-19 clinical research John C Marshall, Srinivas Murthy, Janet Diaz, Neil Adhikari, Derek C Angus, Yaseen M Arabi, et al. (+55)
522 [GO] 2020―Jun―12 Clinical characteristics of COVID-19 in 104 people with SARS-CoV-2 infection on the Diamond Princess cruise ship: a retrospective analysis Sakiko Tabata, Kazuo Imai, Shuichi Kawano, Mayu Ikeda, Tatsuya Kodama, Kazuyasu Miyoshi, et al. (+9)
523 [GO] 2020―Jun―12 Asymptomatic SARS-CoV-2 infection Eng Eong Ooi, Jenny G Low
524 [GO] 2020―Jun―12 SARS-CoV-2 shedding and seroconversion among passengers quarantined after disembarking a cruise ship: a case series Ivan Fan-Ngai Hung, Vincent Chi-Chung Cheng, Xin Li, Anthony Raymond Tam, Derek Ling-Lung Hung, Kelvin Hei-Yeung Chiu, et al. (+26)
525 [GO] 2020―Jun―11 Political casualties of the COVID-19 pandemic The Lancet Infectious Diseases
526 [GO] 2020―Jun―08 Pulmonary post-mortem findings in a series of COVID-19 cases from northern Italy: a two-centre descriptive study Luca Carsana, Aurelio Sonzogni, Ahmed Nasr, Roberta Simona Rossi, Alessandro Pellegrinelli, Pietro Zerbi, et al. (+9)
527 [GO] 2020―Jun―08 Pathologists in pursuit of the COVID-19 culprit Eunhee S Yi, Matthew J Cecchini, Melanie C Bois
528 [GO] 2020―Jun―02 COVID-19 and essential pregnant worker policies Elizabeth S McDonald
529 [GO] 2020―May―29 COVID-19 human challenge studies: ethical issues Euzebiusz Jamrozik, Michael J Selgelid
530 [GO] 2020―May―28 COVID-19 and the difficulty of inferring epidemiological parameters from clinical data Simon N Wood, Ernst C Wit, Matteo Fasiolo, Peter J Green
531 [GO] 2020―May―28 COVID-19 and the difficulty of inferring epidemiological parameters from clinical data - Authors' reply Robert Verity, Lucy Okell, Ilaria Dorigatti, Peter Winskill, Charlie Whittaker, Patrick Walker, et al. (+3)
532 [GO] 2020―May―28 Implication of SARS-CoV-2 evolution in the sensitivity of RT-qPCR diagnostic assays Nuno Sampaio Osório, Margarida Correia-Neves
533 [GO] 2020―May―27 Death threats after a trial on chloroquine for COVID-19 Estella Ektorp
534 [GO] 2020―May―27 Obstacles to COVID-19 control in east Africa Esther Nakkazi
535 [GO] 2020―May―27 COVID-19 lockdown of Roma settlements in Slovakia Ed Holt
536 [GO] 2020―May―22 Hydroxychloroquine prophylaxis for high-risk COVID-19 contacts in India: a prudent approach Praveen Tilangi, Devashish Desai, Adil Khan, Manish Soneja
537 [GO] 2020―May―21 A future vaccination campaign against COVID-19 at risk of vaccine hesitancy and politicisation Patrick Peretti-Watel, Valérie Seror, Sébastien Cortaredona, Odile Launay, Jocelyn Raude, Pierrea Verger, et al. (+6)
538 [GO] 2020―May―21 Individual quarantine versus active monitoring of contacts for the mitigation of COVID-19: a modelling study Corey M Peak, Rebecca Kahn, Yonatan H Grad, Lauren M Childs, Ruoran Li, Marc Lipsitch, Caroline O Buckee
539 [GO] 2020―May―21 COVID-19: when should quarantine be enforced? Chris T Bauch, Madhur Anand
540 [GO] 2020―May―21 RT-PCR for SARS-CoV-2: quantitative versus qualitative Mi Seon Han, Jung-Hyun Byun, Yonggeun Cho, John Hoon Rim
541 [GO] 2020―May―20 Tale of three seeding patterns of SARS-CoV-2 in Saudi Arabia Ziad A Memish, Nawfal Aljerian, Shahul H Ebrahim
542 [GO] 2020―May―18 COVID-19 screening of health-care workers in a London maternity hospital Asma Khalil, Robert Hill, Shamez Ladhani, Katherine Pattisson, Pat O'Brien
543 [GO] 2020―May―18 Silent COVID-19: what your skin can reveal Claudio Guarneri, Emmanuele Venanzi Rullo, Piero Pavone, Massimiliano Berretta, Manuela Ceccarelli, Alfonso Natale, Giuseppe Nunnari
544 [GO] 2020―May―16 The UK hibernated pandemic influenza research portfolio: triggered for COVID-19 Colin R Simpson, Benjamin D Thomas, Kirsty Challen, Daniela De Angelis, Ellen Fragaszy, Steve Goodacre, et al. (+5)
545 [GO] 2020―May―16 Toward a clinically based classification of disease severity for paediatric COVID-19 Danilo Buonsenso, Niccolò Parri, Cristina De Rose, Piero Valentini
546 [GO] 2020―May―16 Toward a clinically based classification of disease severity for paediatric COVID-19 - Authors' reply Dong Chen, Feng Tang, Shushu Lu, Qifa Song
547 [GO] 2020―May―16 Investigation of a COVID-19 outbreak in Germany resulting from a single travel-associated primary case: a case series Merle M Böhmer, Udo Buchholz, Victor M Corman, Martin Hoch, Katharina Katz, Durdica V Marosevic, et al. (+35)
548 [GO] 2020―May―16 Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study Simon de Lusignan, Jienchi Dorward, Ana Correa, Nicholas Jones, Oluwafunmi Akinyemi, Gayatri Amirthalingam, et al. (+16)
549 [GO] 2020―May―16 Importance of precise data on SARS-CoV-2 transmission dynamics control Jan Rybniker, Gerd Fätkenheuer
550 [GO] 2020―May―16 Who is most likely to be infected with SARS-CoV-2? Rachel E Jordan, Peymane Adab
551 [GO] 2020―May―07 Prevention of the cytokine storm in COVID-19 David J M Wright
552 [GO] 2020―May―07 Dearth of infectious diseases physicians as the USA faces a global pandemic Syed M Qasim Hussaini
553 [GO] 2020―May―06 COVID-19 in Cameroon: a crucial equation to resolve Francois-Xavier Mbopi-Keou, Jean-Emmanuel Pondi, Maurice Aurelien Sosso
554 [GO] 2020―May―06 COVID-19 on the African continent Chad R Wells, Jason K Stearns, Pascal Lutumba, Alison P Galvani
555 [GO] 2020―May―06 Testing COVID-19 therapies to prevent progression of mild disease Marc Lipsitch, Stanley Perlman, Matthew K Waldor
556 [GO] 2020―Apr―30 Hypoxaemia related to COVID-19: vascular and perfusion abnormalities on dual-energy CT Min Lang, Avik Som, Dexter P Mendoza, Efren J Flores, Nicholas Reid, Denston Carey, et al. (+5)
557 [GO] 2020―Apr―29 Progressive respiratory failure in COVID-19: a hypothesis Henrik Endeman, Philip van der Zee, Michel E van Genderen, Johannes P C van den Akker, Diederik Gommers
558 [GO] 2020―Apr―28 Pooling of samples for testing for SARS-CoV-2 in asymptomatic people Stefan Lohse, Thorsten Pfuhl, Barbara Berkó-Göttel, Jürgen Rissland, Tobias Geißler, Barbara Gärtner, et al. (+3)
559 [GO] 2020―Apr―27 Estimation of COVID-19 burden in Egypt Mohamed Hassany, Wael Abdel-Razek, Noha Asem, Mohamed AbdAllah, Hala Zaid
560 [GO] 2020―Apr―27 Estimation of COVID-19 burden in Egypt Tarek Sahmoud
561 [GO] 2020―Apr―27 Estimation of COVID-19 burden in Egypt Khaled Elmeleegy
562 [GO] 2020―Apr―27 Estimation of COVID-19 burden in Egypt Ahmed Negida
563 [GO] 2020―Apr―27 Estimation of COVID-19 burden in Egypt - Authors' reply Ashleigh R Tuite, Victoria Ng, Erin Rees, David Fisman, Annelies Wilder-Smith, Kamran Khan, Isaac I Bogoch
564 [GO] 2020―Apr―27 Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study Qifang Bi, Yongsheng Wu, Shujiang Mei, Chenfei Ye, Xuan Zou, Zhen Zhang, et al. (+16)
565 [GO] 2020―Apr―27 Impact of contact tracing on SARS-CoV-2 transmission Kaiyuan Sun, Cécile Viboud
566 [GO] 2020―Apr―22 No SARS-CoV-2 detected in amniotic fluid in mid-pregnancy Nan Yu, Wei Li, Qingling Kang, Wanjiang Zeng, Ling Feng, Jianli Wu
567 [GO] 2020―Apr―21 Mediastinal lymphadenopathy in patients with severe COVID-19 Xavier Valette, Damien du Cheyron, Suzanne Goursaud
568 [GO] 2020―Apr―21 Plea for multitargeted interventions for severe COVID-19 Benjamin Jean Gaborit, Jean-François Bergmann, Cristina Mussini, Jose Ramon Arribas, Georg Behrens, Sharon Walmsley, et al. (+2)
569 [GO] 2020―Apr―21 The important role of serology for COVID-19 control Amy K Winter, Sonia T Hegde
570 [GO] 2020―Apr―21 Targeting COVID-19 interventions towards migrants in humanitarian settings Sally Hargreaves, Dominik Zenner, Kolitha Wickramage, Anna Deal, Sally E Hayward
571 [GO] 2020―Apr―21 Projecting the demand for ventilators at the peak of the COVID-19 outbreak in the USA Chad R Wells, Meagan C Fitzpatrick, Pratha Sah, Affan Shoukat, Abhishek Pandey, Abdulrahman M El-Sayed, et al. (+3)
572 [GO] 2020―Apr―21 Connecting clusters of COVID-19: an epidemiological and serological investigation Sarah Ee Fang Yong, Danielle Elizabeth Anderson, Wycliffe E Wei, Junxiong Pang, Wan Ni Chia, Chee Wah Tan, et al. (+14)
573 [GO] 2020―Apr―21 Two Middle East respiratory syndrome vaccines: first step for other coronavirus vaccines? Kayvon Modjarrad, Jerome H Kim
574 [GO] 2020―Apr―21 Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial Pedro M Folegatti, Mustapha Bittaye, Amy Flaxman, Fernando Ramos Lopez, Duncan Bellamy, Alexandra Kupke, et al. (+24)
575 [GO] 2020―Apr―21 Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial Till Koch, Christine Dahlke, Anahita Fathi, Alexandra Kupke, Verena Krähling, Nisreen M A Okba, et al. (+19)
576 [GO] 2020―Apr―17 Chloroquine or hydroxychloroquine for prophylaxis of COVID-19 Nicola Principi, Susanna Esposito
577 [GO] 2020―Apr―17 Hydroxychloroquine prophylaxis for COVID-19 contacts in India Sahaj Rathi, Pranav Ish, Ashwini Kalantri, Shriprakash Kalantri
578 [GO] 2020―Apr―17 Gaps in India's preparedness for COVID-19 control Patralekha Chetterje
579 [GO] 2020―Apr―17 COVID-19 disrupts vaccine delivery Roxanne Nelson
580 [GO] 2020―Apr―17 COVID-19 in Latin America Talha Burki
581 [GO] 2020―Apr―17 Rural areas at risk during COVID-19 pandemic Peter Ranscombe
582 [GO] 2020―Apr―17 COVID-19: endgames The Lancet Infectious Diseases
583 [GO] 2020―Apr―16 Protecting workers aged 60-69 years from COVID-19 Judith R Glynn
584 [GO] 2020―Apr―15 Smell and taste dysfunction in patients with COVID-19 Michael S Xydakis, Puya Dehgani-Mobaraki, Eric H Holbrook, Urban W Geisthoff, Christian Bauer, Charlotte Hautefort, et al. (+4)
585 [GO] 2020―Apr―15 Utility of hyposmia and hypogeusia for the diagnosis of COVID-19 François Bénézit, Paul Le Turnier, Charles Declerck, Cécile Paillé, Matthieu Revest, Vincent Dubée, et al. (+30)
586 [GO] 2020―Apr―15 COVID-19 and the coming epidemic in US immigration detention centres Jaimie P Meyer, Carlos Franco-Paredes, Parveen Parmar, Faiza Yasin, Matthew Gartland
587 [GO] 2020―Apr―09 A Spanish-translated clinical algorithm for management of suspected SARS-CoV-2 infection in pregnant women Raigam J Martinez-Portilla, Anna Goncé, Ameth Hawkins-Villarreal, Francesc Figueras
588 [GO] 2020―Apr―08 Making decisions to mitigate COVID-19 with limited knowledge Weituo Zhang, Bi-yun Qian
589 [GO] 2020―Apr―08 Invisible spread of SARS-CoV-2 Nian Xiong, Tao Wang, Zhicheng Lin
590 [GO] 2020―Apr―08 Invisible spread of SARS-CoV-2 - Authors' reply Adam J Kucharski, Rosalind M Eggo
591 [GO] 2020―Apr―04 Baricitinib for COVID-19: a suitable treatment? Ennio G Favalli, Martina Biggioggero, Gabriella Maioli, Roberto Caporali
592 [GO] 2020―Apr―04 Baricitinib for COVID-19: a suitable treatment? - Authors' reply Peter J Richardson, Mario Corbellino, Justin Stebbing
593 [GO] 2020―Apr―03 From China: hope and lessons for COVID-19 control Andrew S Azman, Francisco J Luquero
594 [GO] 2020―Apr―02 Evolving epidemiology and transmission dynamics of coronavirus disease 2019 outside Hubei province, China: a descriptive and modelling study Juanjuan Zhang, Maria Litvinova, Wei Wang, Yan Wang, Xiaowei Deng, Xinghui Chen, et al. (+18)
595 [GO] 2020―Apr―01 Using observational data to quantify bias of traveller-derived COVID-19 prevalence estimates in Wuhan, China Rene Niehus, Pablo M De Salazar, Aimee R Taylor, Marc Lipsitch
596 [GO] 2020―Apr―01 Modelling COVID-19 transmission: from data to intervention Zhongwei Jia, Zuhong Lu
597 [GO] 2020―Mar―31 Estimating case fatality rates of COVID-19 David Dongkyung Kim, Akash Goel
598 [GO] 2020―Mar―31 Estimating case fatality rates of COVID-19 Marc Lipsitch
599 [GO] 2020―Mar―31 Estimating case fatality rates of COVID-19 Piotr Spychalski, Agata Błażyńska-Spychalska, Jarek Kobiela
600 [GO] 2020―Mar―31 SARS-CoV-2: a time for clear and immediate action Gregory A Poland
601 [GO] 2020―Mar―30 Likelihood of survival of coronavirus disease 2019 Shigui Ruan
602 [GO] 2020―Mar―30 Estimates of the severity of coronavirus disease 2019: a model-based analysis Robert Verity, Lucy C Okell, Ilaria Dorigatti, Peter Winskill, Charles Whittaker, Natsuko Imai, et al. (+27)
603 [GO] 2020―Mar―30 Will financial innovation transform pandemic response? Susan L Erikson, Leigh Johnson
604 [GO] 2020―Mar―27 The many estimates of the COVID-19 case fatality rate Dimple D Rajgor, Meng Har Lee, Sophia Archuleta, Natasha Bagdasarian, Swee Chye Quek
605 [GO] 2020―Mar―27 Clinical and virological data of the first cases of COVID-19 in Europe: a case series Francois-Xavier Lescure, Lila Bouadma, Duc Nguyen, Marion Parisey, Paul-Henri Wicky, Sylvie Behillil, et al. (+17)
606 [GO] 2020―Mar―27 Understanding COVID-19: what does viral RNA load really mean? Gavin M Joynt, William KK Wu
607 [GO] 2020―Mar―26 US public health budget cuts in the face of COVID-19 Sharmila Devi
608 [GO] 2020―Mar―26 Estimation of the COVID-19 burden in Egypt through exported case detection Ashleigh R Tuite, Victoria Ng, Erin Rees, David Fisman, Annelies Wilder-Smith, Kamran Khan, Isaac I Bogoch
609 [GO] 2020―Mar―26 CT screening for early diagnosis of SARS-CoV-2 infection Yongshun Huang, Weibin Cheng, Na Zhao, Hongying Qu, Junzhang Tian
610 [GO] 2020―Mar―26 CT screening for early diagnosis of SARS-CoV-2 infection - Authors' reply Heshui Shi, Xiaoyu Han, Yukun Cao, Osamah Alwalid, Chuansheng Zheng
611 [GO] 2020―Mar―25 COVID-19 in children: the link in the transmission chain Alyson A Kelvin, Scott Halperin
612 [GO] 2020―Mar―25 Clinical and epidemiological features of 36 children with coronavirus disease 2019 (COVID-19) in Zhejiang, China: an observational cohort study Haiyan Qiu, Junhua Wu, Liang Hong, Yunling Luo, Qifa Song, Dong Chen
613 [GO] 2020―Mar―24 Management of pregnant women infected with COVID-19 Yongwen Luo, Kai Yin
614 [GO] 2020―Mar―24 Clinical features and obstetric and neonatal outcomes of pregnant patients with COVID-19 in Wuhan, China: a retrospective, single-centre, descriptive study Nan Yu, Wei Li, Qingling Kang, Zhi Xiong, Shaoshuai Wang, Xingguang Lin, et al. (+8)
615 [GO] 2020―Mar―23 Scientific and ethical basis for social-distancing interventions against COVID-19 Joseph A Lewnard, Nathan C Lo
616 [GO] 2020―Mar―23 COVID-19 and medical education Hanad Ahmed, Mohammed Allaf, Hussein Elghazaly
617 [GO] 2020―Mar―23 The first COVID-19 case in Afghanistan acquired from Iran Sayed H Mousavi, Jaffer Shah, Hoang T N Giang, Tareq M A Al-Ahdal, Shafi U Zahid, Fardina Temory, et al. (+3)
618 [GO] 2020―Mar―23 Interventions to mitigate early spread of SARS-CoV-2 in Singapore: a modelling study Joel R Koo, Alex R Cook, Minah Park, Yinxiaohe Sun, Haoyang Sun, Jue Tao Lim, et al. (+2)
619 [GO] 2020―Mar―23 Temporal profiles of viral load in posterior oropharyngeal saliva samples and serum antibody responses during infection by SARS-CoV-2: an observational cohort study Kelvin Kai-Wang To, Owen Tak-Yin Tsang, Wai-Shing Leung, Anthony Raymond Tam, Tak-Chiu Wu, David Christopher Lung, et al. (+19)
620 [GO] 2020―Mar―23 SARS-CoV-2: virus dynamics and host response Yu Chen, Lanjuan Li
621 [GO] 2020―Mar―19 Viral dynamics in mild and severe cases of COVID-19 Yang Liu, Li-Meng Yan, Lagen Wan, Tian-Xin Xiang, Aiping Le, Jia-Ming Liu, et al. (+3)
622 [GO] 2020―Mar―19 Estimation of COVID-19 outbreak size in Italy Ashleigh R Tuite, Victoria Ng, Erin Rees, David Fisman
623 [GO] 2020―Mar―17 COVID-19 in pregnant women Manuel B Schmid, Jehudith Fontijn, Nicole Ochsenbein-Kölble, Christoph Berger, Dirk Bassler
624 [GO] 2020―Mar―17 COVID-19 in pregnant women - Authors' reply David Baud, Eric Giannoni, Léo Pomar, Xiaolong Qi, Karin Nielsen-Saines, Didier Musso, Guillaume Favre
625 [GO] 2020―Mar―17 Disease X: accelerating the development of medical countermeasures for the next pandemic Shmona Simpson, Michael C Kaufmann, Vitaly Glozman, Ajoy Chakrabarti
626 [GO] 2020―Mar―13 COVID-19, a pandemic or not? The Lancet Infectious Diseases
627 [GO] 2020―Mar―12 Real estimates of mortality following COVID-19 infection David Baud, Xiaolong Qi, Karin Nielsen-Saines, Didier Musso, Léo Pomar, Guillaume Favre
628 [GO] 2020―Mar―12 SARS-CoV-2 RNA more readily detected in induced sputum than in throat swabs of convalescent COVID-19 patients Huanqin Han, Qingfeng Luo, Fan Mo, Lieming Long, Weiqiang Zheng
629 [GO] 2020―Mar―12 Early dynamics of transmission and control of COVID-19: a mathematical modelling study Adam J Kucharski, Timothy W Russell, Charlie Diamond, Yang Liu, John Edmunds, Sebastian Funk, et al. (+16)
630 [GO] 2020―Mar―09 Covert COVID-19 and false-positive dengue serology in Singapore Gabriel Yan, Chun Kiat Lee, Lawrence T M Lam, Benedict Yan, Ying Xian Chua, Anita Y N Lim, et al. (+9)
631 [GO] 2020―Mar―09 Outbreak investigation for COVID-19 in northern Vietnam Hai Nguyen Thanh, Truong Nguyen Van, Huong Ngo Thi Thu, Binh Nghiem Van, Binh Doan Thanh, Ha Phung Thi Thu, et al. (+5)
632 [GO] 2020―Mar―09 COVID-19 with spontaneous pneumomediastinum Changyu Zhou, Chen Gao, Yuanliang Xie, Maosheng Xu
633 [GO] 2020―Mar―05 Taking the right measures to control COVID-19 Yonghong Xiao, Mili Estee Torok
634 [GO] 2020―Mar―05 Can we contain the COVID-19 outbreak with the same measures as for SARS? Annelies Wilder-Smith, Calvin J Chiew, Vernon J Lee
635 [GO] 2020―Mar―03 Guidelines for pregnant women with suspected SARS-CoV-2 infection Guillaume Favre, Léo Pomar, Xiaolong Qi, Karin Nielsen-Saines, Didier Musso, David Baud
636 [GO] 2020―Feb―29 A family cluster of SARS-CoV-2 infection involving 11 patients in Nanjing, China Rui Huang, Juan Xia, Yuxin Chen, Chun Shan, Chao Wu
637 [GO] 2020―Feb―27 Convalescent plasma as a potential therapy for COVID-19 Long Chen, Jing Xiong, Lei Bao, Yuan Shi
638 [GO] 2020―Feb―27 COVID-19: combining antiviral and anti-inflammatory treatments Justin Stebbing, Anne Phelan, Ivan Griffin, Catherine Tucker, Olly Oechsle, Dan Smith, Peter Richardson
639 [GO] 2020―Feb―25 Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study Heshui Shi, Xiaoyu Han, Nanchuan Jiang, Yukun Cao, Osamah Alwalid, Jin Gu, et al. (+2)
640 [GO] 2020―Feb―25 COVID-19 pneumonia: what has CT taught us? Elaine Y P Lee, Ming-Yen Ng, Pek-Lan Khong
641 [GO] 2020―Feb―25 Viral load of SARS-CoV-2 in clinical samples Yang Pan, Daitao Zhang, Peng Yang, Leo L M Poon, Quanyi Wang
642 [GO] 2020―Feb―19 The first Vietnamese case of COVID-19 acquired from China Le Van Cuong, Hoang Thi Nam Giang, Le Khac Linh, Jaffer Shah, Le Van Sy, Trinh Huu Hung, et al. (+4)
643 [GO] 2020―Feb―19 An interactive web-based dashboard to track COVID-19 in real time Ensheng Dong, Hongru Du, Lauren Gardner
644 [GO] 2020―Feb―19 Open access epidemiological data from the COVID-19 outbreak Bo Xu, Moritz U G Kraemer, Bo Xu, Bernardo Gutierrez, Sumiko Mekaru, Kara Sewalk, et al. (+14)
645 [GO] 2020―Feb―19 Initiation of a new infection control system for the COVID-19 outbreak Xuejiao Chen, Junzhang Tian, Guanming Li, Guowei Li
646 [GO] 2020―Feb―19 Asymptomatic cases in a family cluster with SARS-CoV-2 infection Xingfei Pan, Dexiong Chen, Yong Xia, Xinwei Wu, Tangsheng Li, Xueting Ou, et al. (+2)
647 [GO] 2020―Feb―17 Challenges of coronavirus disease 2019 The Lancet Infectious Diseases
648 [GO] 2020―Feb―17 Outbreak of coronavirus disease 2019 Talha Burki
649 [GO] 2020―Feb―10 The first 2019 novel coronavirus case in Nepal Anup Bastola, Ranjit Sah, Alfonso J Rodriguez-Morales, Bibek Kumar Lal, Runa Jha, Hemant Chanda Ojha, et al. (+6)
650 [GO] 2020―Feb―07 Game consumption and the 2019 novel coronavirus Jie Li, Jun Li, Xiaoru Xie, Xiaomei Cai, Jian Huang, Xuemei Tian, Hong Zhu
651 [GO] 2020―Feb―07 Pandemic potential of 2019-nCoV Robin Thompson
652 [GO] 2020―Jan―21 Oral influenza vaccination-a possible solution for the next pandemic? Larisa Rudenko, Irina Isakova-Sivak
653 [GO] 2019―Dec―10 Stories of the 1918 influenza pandemic and its legacy Marta Gritti
 [1] 

653 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.161 sec